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1 Introduction 
 
1.1 Epilepsy 
 
Up to 10% of the population is affected by one seizure during lifetime. Such one-
time event does not necessarily lead to a manifestation of epilepsy. Nevertheless, 
about 50 million people suffer from epilepsy, which is therefore regarded as one of 
the most common serious brain disorders worldwide. Approximately 0.1% to 1.0% 
of the population is affected by epilepsy, often accompanied with e.g. physical 
hazards due to unpredictability of seizure occurrence as well as social and 
economic burdens (1-4). 
The general public commonly associates epilepsy with the incidence of tonic-
clonic seizures, usually termed as ‘grand mal seizures’. In contrast to this, the 
clinical view of epilepsy is much more distinct. In order to establish a common 
definition of epilepsy, the International League Against Epilepsy (ILAE) and the 
International Bureau for Epilepsy (IBE) accepted the definition of epileptic seizures 
as ‘a transient occurrence of signs and/or symptoms due to abnormal excessive or 
synchronous neuronal activity in the brain (2, 5). This somewhat vague definition 
of epilepsy implicates a diverse etiology and symptoms of epileptic seizures. The 
ILAE Proposal for Revised Terminology for Organization of Seizure and Epilepsies 
2010 distinguishes between generalized seizures, characterized by the arising and 
the propagation within bilaterally distributed networks, and focal seizures, which 
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originate within networks limited to one hemisphere. The appearance of 
generalized seizures is diverse, ranging from tonic-clonic over absence, clonic, 
tonic, atonic to myoclonic seizures. For focal seizures, which were formally 
subdivided into simple partial (consciousness not impaired) and complex partial 
seizures (accompanied by impairment of consciousness), no specific classification 
is longer recommended. Since 2010 the ILAE suggests to classify focal seizures 
by their semiologic features, such as by the occurrence and kind of auras, motor- 
and autonomic impairment and the awareness and responsiveness of patients (5, 
6).  
The underlying causes leading to epilepsy are characterized in the ILAE Proposal 
for Revised Terminology For Organization of Seizure and Epilepsies 2010. This 
report distinguishes between genetic, structural/ metabolic and ‘unknown causes’ 
for seizures. In their terms genetically evoked epilepsies are a direct effect of a 
genetic defect, thereby seizures represent the core symptoms of the disorder. This 
concept accounts for instance for channelopathies. Furthermore, they concretize 
that the underlying cause of structural/ metabolic epilepsies are distinct disorders 
associated with a higher risk of developing epilepsy. This includes on the one 
hand, acquired structural impairments such as stroke and trauma and on the other 
hand, lesions of genetic origin like tuberous sclerosis or cortical malformations. 
Thereby, the disorder constitutes the link between genetic alteration and epilepsy. 
In addition, epilepsies of ‘unknown causes’ are characterized as syndromes with 
yet unidentified nature of the underlying pathomechanisms (5, 6). 
During the last decades many antiepileptic drugs have been developed and in the 
majority, patients’ seizures (approximately 70%) can be controlled effectively with 
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the administration of anticonvulsants. Nevertheless, about 30% of people suffering 
from epilepsy do not respond to proper drug treatment (7). These patients are 
termed as pharmacoresistant. Evidently, particularly pharmacoresistant epilepsies 
comprise clinical, social and economic challenges, as chronic epilepsy is often 
accompanied with social isolation, depression and stigmatization (8). In addition to 
that, intractable epilepsies have a health economical impact, since medical costs 
for patients suffering from pharmacoresistant epilepsy are significantly higher ($ 
10.000/year) than for well-controlled patients ($ 2.000/year) (9). 
 
 
1.2 Focal epilepsies 
 
The reasons leading to the manifestation of epilepsy are diverse as well the 
localization of epileptogenic tissue in the brain. Focally induced seizures can origin 
from different parts of the brain, e.g. the parietal-, the frontal-, the occipital- or the 
temporal lobe. Within the group of focally induced seizures, epilepsies arising from 
the temporal lobe comprise the most common group of refractory epilepsies (10). 
Obviously, pharmacoresistance represents a crucial clinical problem in seizure 
treatment. In the majority of cases epilepsy surgery is the only appropriate 
treatment for patients suffering from intractable epilepsy (11). 
Several factors, such as an early onset of seizures, history of status epilepticus 
and certain structural abnormalities like focal cortical dysplasia or gangliogliomas, 
have been correlated with drug-resistant epilepsy (7). In 93% of patients with focal 
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temporal lobe seizures undergoing epilepsy surgery distinct histopathological 
patterns are present. These include for instance hippocampal sclerosis, low-grade 
brain tumors, cortical malformations, malformative vascular lesions, glial scars and 
encephalitic lesions. In these cases the cause of epilepsy is symptomatic. Merely 
a small proportion of temporal lobe epilepsy (7%) is of unknown pathology, as 
histomorphological analyses do not succeed to recognize pathological alterations 
(12, 13).  
A hallmark of temporal lobe epilepsy is the manifestation of seizures in 
adolescents or young adults. Typical temporal lobe seizures comprise focal 
seizures accompanied with or without the impairment of consciousness. Seizures 
can generalize and often manifest with epigastric auras and chewing-, licking- or 
swallowing automatisms (14).  
Symptomatic temporal lobe epilepsy can further be subdivided into mesial 
temporal lobe epilepsy and neocortical temporal lobe epilepsy. Mesial temporal 
lobe seizures affect the hippocampal structures composed of the ammon’s horn 
(Cornu Ammonis), Gyrus Dentatus and Subiculum (12). In a substantial proportion 
of resected hippocampi (60%) from temporal lobe epilepsy patients, Ammon’s 
horn sclerosis (AHS) is diagnosed as the symptomatic cause of seizures (15). In 
these specimens segmental neuronal cell loss is especially found in the CA1, CA3 
und CA4 regions, while CA2 and dentate gyrus granule cells are less affected 
(16).  
Focal epileptic seizures originating from neocortical areas are termed as lateral 
temporal lobe epilepsy. Benign brain tumors are most commonly identified as the 
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underlying cause of neocortical temporal lobe epilepsy. The majority of these low-
grade neoplasms comprises gangliogliomas (17).  
 
 
1.3 Gangliogliomas 
 
Gangliogliomas are benign brain tumors with only rare malignant progression. 
Commonly, they are encountered within the temporal lobe. The majority in general 
brain tumor series is classified as WHO grade I tumors. Gangliogliomas are rare 
neoplasms, with an incidence of only 1.3% in large brain tumor series, but 
nevertheless they represent the most frequent tumor entity in young adults 
suffering from focal chronic pharmacoresistant epilepsy (18-20).  
Epilepsy patients suffering from gangliogliomas often do not respond to 
antiepileptic drug treatment (20). In these cases neurosurgical removal of the 
epileptic tissue has to be taken into account in order to gain seizure control. The 
majority of ganglioglioma patients benefits from tumor resection. Studies implicate 
that 75% of patients may be regarded as seizure free after surgery. 6% of patients 
reveal a positive postoperative course of disease with remission of initial seizures. 
However, 1% of patients exhibit seizure relapse after initial seizure relief and 18% 
of ganglioglioma patients still suffer from persisting seizures after tumor removal 
(21). 
Gangliogliomas can occur throughout the central nervous system, yet typically 
localized in the temporal lobe. They reveal a biphasic architecture, composed of 
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dysplastic and sometimes-binucleated neurons as well as of highly differentiated 
and proliferative glial cells (Figure 1.3.1). Histological hallmarks of these 
neoplasms are a perisomatic accumulation of Synaptophysin as well as the 
expression of the stem cell marker CD34 in so-called ‘satellite cells’. Intriguingly, 
CD34 does not occur in normal brain tissue and its expression in ganglioglioma 
tissue may suggest an origin of these tumors from developmentally compromised 
precursor lesions (18, 20, 22). Further histopathological attributes frequently 
encountered in gangliogliomas include calcifications, lymphoid infiltrates along 
perivascular spaces or within the tumor parenchyma and prominent capillary 
network (20). 
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Figure 1.3.1: Histological and immunohistochemical characteristics of 
gangliogliomas. (A) Gangliogliomas are characterized by an admixture of glial and 
dysmorphic neuronal elements (hematoxylin & eosin (H&E) staining); arrows point 
to clusters of dysmorphic neurons). (B) Dysmorphic, occasionally bi-nucleated 
neuronal ganglioglioma elements are irregularly oriented within the ganglioglioma 
and (C) show strong perisomatic immunoreactivity when using antibodies against 
Synaptophysin. (D) Neurofilament (NFM) staining prominently demonstrates the 
aberrant structure and shape of ganglioglioma neuronal components’ processes 
that obviously are subject of impaired arborization (NFM IHC; arrows point to 
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strikingly dysmorphic neuronal processes). (E) Immunohistochemistry (IHC) with 
antibodies against glial fibrillary acidic protein (GFAP) reveals a prominent, process 
rich astroglial ganglioglioma component that resembles the fibrillary matrix in H&E 
stainings (GFAP IHC; arrow points to clusters of dysmorphic neurons located in the 
astroglial matrix). (F) So-called ‘satellite cells’ with expression of the oncofetal 
protein CD43 in the proximity of gangliogliomas point towards a developmentally 
compromized origin of gangliogliomas (CD34 IHC; arrows point to ‘satellite 
clusters’). Scale bar: A, B, E, F: 200m; C, D: 50m. 
 
 
1.4 Molecular pathological aspects of gangliogliomas  
 
Pathogenic mechanisms leading to focal hyperexcitability of ganglioglioma tissue 
still have to be uncovered. Nowadays, two hypotheses are under consideration. 
On the one hand it is taken into account, that dysplastic neurons within the 
neoplasms themselves provoke synchronized discharges. This presumption is 
supported by immunohistochemical studies indicating that glutamatergic 
transmission mechanisms are crucially involved in epileptogenicity of glioneuronal 
tumors (19, 23). Another explanation for hyperexcitability relies on the assumption 
of tumor-associated epileptic changes in adjacent non-tumorous brain tissue. This 
idea is underlined by alterations of the composition of neuroactive proteins within 
perilesional brain areas and by the clinical observation of hyperexcitable tissue 
outside of the tumor entity itself (24, 25). To date, the molecular pathomechanisms 
leading to the manifestation of gangliogliomas still remain enigmatic.  
The differentiated glioneuronal appearance as well as the focal nature and the 
benign clinical course of gangliogliomas point to an origin from developmentally 
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compromised precursor lesions (18, 19, 26). The presence of the stem cell marker 
CD34 supports the idea of a maldevelopmental origin of these neoplasms (18).  
Additionally, ongoing discussions deal with the issue whether the glial part, 
neuronal cells or both compartments of gangliogliomas constitute the neoplastic 
unit of these tumors. While on the one hand studies, e.g. by Becker et al. (2001), 
assume that glial cells represent the neoplastic factor of gangliogliomas, in this 
particular case due to mutational events of the tumor suppressor gene TCS2 in 
glial cells, other investigations by Zhu et al. (1997) suggest both glial and neuronal 
cells as neoplastic origin of gangliogliomas (27-30).  
Recently, two independent investigations by Schindler et al. (2011) and Koelsche 
et al. (2013) detected an increased rate of BRAF V600 mutations in 
gangliogliomas. In these two studies approximately 20%, respectively 58% of 
analyzed gangliogliomas carried the BRAF V600 mutation (30, 31).  
BRAF participates in the RAS/RAF/MEK/ERK pathway, a signal transduction 
cascade, which transmits extracellular signals to the nucleus and thereby 
influences cell proliferation, differentiation and survival. The BRAF V600 mutation, 
with a base exchange from thymidine to adenosine at c.1799 causes a 
replacement of valine by glutamic acid at position 600. By mimicking 
phosphorylation of amino acids T599 and S602, the BRAF V600 mutation leads to 
a constitutive activation of the BRAF protein (32). 
Detailed characterization by Koelsche et al. (2013) of the BRAF V600 mutation in 
gangliogliomas uncovered, that mutant BRAF V600 protein is primarily present in 
the neuronal compartment of gangliogliomas. This finding once more fosters the 
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debate, whether neurons jointly with glial cells constitute the neoplastic elements 
of gangliogliomas (30).  
Diagnosis of gangliogliomas can be challenging, as morphological appearances 
may be very similar to those observed in cortical infiltrating diffuse astrocytomas. 
Quite recently, studies implicate that neuropathological differentiation of both 
tumors can be facilitated by immunohistochemical detection of IDH1 mutations, 
which are present in 75% of diffuse astrocytomas, but rare in gangliogliomas (28, 
33).  
In addition to that, it is important to stress, that different genes with mutational 
events in other brain tumor, for instance TP53, PTEN, EGF and various 
chromosomal loci, are rarely altered in gangliogliomas (34, 35).  
Microarray mRNA expression analysis by Fassunke et al. (2008) identified 94 
differentially expressed genes in ganglioglioma vs. control tissue. Several of these 
genes are related to regulation of chromatin status, intracellular signal 
transduction, development and cellular differentiation. The LIM-domain-binding 2 
(LDB2) transcript was characterized as one of the most reduced transcripts in 
gangliogliomas vs. control tissue (26). LDB2 interacts with the LIM domain of two 
transcription factor families, LIM-homeodomain proteins (LIM-HD) and LIM-only 
proteins. The interplay between LDB and LIM domains seems to be essential for 
neuronal development (36). 
Such findings, together with the putative malformative nature of gangliogliomas, 
draw genes and signal transduction cascades related to cellular differentiation and 
migration into the center of attention (20). 
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In this context it is important to note, that microarray expression data by Fassunke 
et al. (2008) demonstrate significantly reduced levels of LRP12 transcripts in 
gangliogliomas as compared to adjacent control tissue (Figure 1.4.1). This is 
interesting, as LRP12 is supposed to be critical during brain development and 
additionally believed to act as a tumor suppressor in non-cerebral neoplasms (37, 
38).  
 
 
 
Figure 1.4.1: mRNA transcript analysis reveals less abundant mRNA expression of 
LRP12 in ganglioglioma vs. control brain tissue (n=6 for GGs and controls; U-test, 
p*<0.05). Ganglioglioma and control tissue was obtained from the same patient 
(modified from (26)). 
 
In order to determine the cause of less abundant LRP12 mRNA levels in 
gangliogliomas, single-strand conformation polymorphism (SSCP) analysis was 
carried out by Jana Fassunke as previously described (27). SSCP analysis is a 
common diagnostic tool for detection of base alterations in DNA samples (39). 
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Nowadays, coding mutations are accepted as general mechanism of functional 
gene inactivation in brain tumors (40, 41). Interestingly, SSCP analyses of the 
LRP12 gene in ganglioglioma biopsy tissue of patients who underwent surgical 
removal of the tumor revealed no mutations or increased allelic variants in the 
LRP12 coding region. Nevertheless, SSCP and sequencing analyses of the 
LRP12 promoter area revealed a single nucleotide polymorphism (SNP) in the 
LRP12 promoter region of ganglioglioma patients. 
Thus, the finding of low levels of LRP12 mRNA in gangliogliomas points to LRP12 
as an interesting candidate gene potentially involved in the pathogenesis of 
epilepsy-associated gangliogliomas.  
 
 
1.5 LRP12  
 
The low-density lipoprotein receptor-related protein 12 (LRP12), formerly 
designated as ST7, was first described by Qing et al. in 1999. Using differential 
mRNA display to detect gene expression levels of human non-tumorigenic 
fibroblast cells (MSU-1 cells) and their carcinogen transformed counterpart 
(6A/SB1 cells), they discovered a 6-fold lower mRNA expression in 6a/SB1 cells 
compared to MSU-1.1 cells of a thitherto unknown gene. Furthermore, down-
regulation of LRP12 mRNA levels in 5 out of 15 MSU-1.1 derived cells as well as 
low or no detectable mRNA levels in 10 out of 15 tumor-derived cell lines from 
fibrosarcoma, osteosarcoma and neurofibrosarcoma patients was described. 
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Additionally, only low protein levels were detected in several tumorigenic fibroblast 
cell lines. Taken together Qing et al. concluded, that the absence of mRNA and 
protein in several tumorigenic cell lines points to a function of this gene as a tumor 
suppressor. Hence, this newly discovered gene was named ‘suppressor of 
tumorigenicity 7’ (ST7). Further characterization revealed an abundant mRNA 
expression in heart and skeletal muscles and a more moderate presence for 
instance in brain, lung and pancreas. ST7 mRNA was barely detectable in tissues 
containing large amounts of epithelial cells such as liver or kidney. Cloning of a 
full-length human ST7 cDNA uncovered a protein of 859 amino acids with an 
estimated molecular weight of 92.8kDA. Analysis of the primary structure 
suggested ST7 to be a single pass transmembrane protein with no significant 
similarity to other known proteins (38).  
In 2003, ST7 was characterized in more detail by Battle et al.. With the help of 
proteomic tools such as similarity searches and sequence alignments it became 
clear that ST7 is closely related to LRP3, a gene encoding a protein belonging to 
the low-density lipoprotein receptor (LDLR) superfamily. The similarity between 
ST7 and LRP3 strongly suggested, that ST7 is a novel LRP and should therefore 
be named LRP12. The comparison of amino acid residues 27-604 (LRP12) and 
residues 42-627 (LRP3) demonstrated the proteins being 50% identical and 66% 
similar (42, 43). In addition, Sugiyama et al. discovered a novel murine gene, 
LRP9, closely related to LRP12 and LRP3 (43, 44). All three proteins have certain 
features in common, which suggest, that they constitute a subfamily of the LDLR 
superfamily. These similarities comprise for instance their extracellular regions, 
which are composed of the same types of domains, arranged in the same fashion. 
In addition to that, the juxtamembrane regions of their cytoplasmic domains are 
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highly conserved, strongly suggesting that these regions are of functional 
relevance. Furthermore putative sequences for endocytosis and motifs potentially 
involved in signal transduction are found in all three cytoplasmic tails (43).  
Analysis of the LRP12 protein structure revealed the existence of an extracellular 
domain with a signal sequence peptide motif (amino acid residues 1-27). 
Furthermore, the extracellular domain adheres 5 LDLRA domains arranged in two 
clusters and followed by two CUB domains (43).  
LDLRA domains, commonly existing in all LDLR superfamily members and 
eponymous for this protein family, seem to function as ligand binding sites (45). 
CUB domains are thought to participate in protein-protein interactions (46, 47).  
LRP12 is a putative transmembrane protein with a single hydrophobic 
transmembrane helix flanked by positively charged residues. The c-terminal 
cytoplasmic tail is composed of several motifs thought to function in endocytosis 
and signal transduction (Figure 1.5.1) (43). 
 
 
 
Figure 1.5.1: Protein structure of the putative single pass transmembrane protein 
LRP12 (modified from (43)). 
Introduction  
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Using yeast-two-hybrid and co-immunoprecipitation assays, Battle at al. (2003) 
were able to identify RACK1, MIBP and SARA as interaction partners of LRP12 in 
vitro (43). 
RACK1 (receptor for activated C kinase 1) is a scaffold protein involved in several 
signal transduction cascades. It was first identified as a shuttling protein for 
activated protein kinase C (PKC) (48, 49). MIBP is an integrin binding protein 
functioning in signal transduction pathways regulating myogenesis (50). SARA is 
thought to serve as a scaffold protein, shuttling SMAD2 and SAMD3 to the 
cytoplasmic domains of the TGF- receptor (51).  
More recent studies about Lrp12 by Schneider et al. (2010) suggest an abundant 
Lrp12 expression during rodent cortical development. In this context Lrp12 is 
highly expressed in a subpopulation of postmitotic preplate neurons undergoing 
tangential migration and forming axonal projections to the contralateral 
hemisphere during early and mid-preplate stages. Thereby, Lrp12 can be used as 
a marker for migrating neurons (37).  
Murine Lrp12 is a homologue of the C. elegans neuroblast migration gene mig-13. 
MIG-13 is linked to Wnt-pathway and seems to be essential for accurate neuronal 
migration processes in C. elegans (52, 53). 
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1.6 Cortical development 
 
The mammalian cortex is a complex structure with a common plan of layers, 
different cell types and connections. During the last three decades studies gave 
new insights into the mechanisms of cortical development regarding cell division, 
programmed cell death and neuronal migration. During mammalian corticogenesis 
the ventricular zone (VZ) and the subventricular zone (SVZ) line the cerebral 
ventricles (54). Three types of cortical precursor have been found to play a role for 
neurogenesis. These precursors are radial glial cells (RGS), which are restricted to 
the rodent VZ (55-58), short neural precursors (SNPs) (59) and intermediate 
progenitor cells (IPCs) (60, 61).  
During embryogenesis, on day E17 SNPs as well as RGCs divide at the apical 
surface of the VZ. (59, 62). On the contrary, IPCs divide away form the ventricular 
surface in the VZ and in the SVZ (57, 60). After division, postmitotic neurons 
migrate away from the VZ and SVZ towards the marginal zone (MZ), forming the 
cortical plate (Figure 1.6.1). Later in adult animal this cortical plate will depict the 
six-layered cerebral cortex. Thereby, cortical neurons destined for the lower 
cortical layers are generated at the VZ, whereas neurons later comprising the 
upper cortical layers arise in the SVZ (63, 64).  
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Figure 1.6.1: Neuronal progenitors and neuronal postmitotic migration during 
cortical development at day E17 (modified from (64)). 
 
In addition to neurons, mammalian cortices consist of glial cells, which e.g. provide 
structural support, regulate water balance or ion distribution. Both neurons and 
glial cells can origin from the same type of progenitor cells. Generally, evolutionary 
higher developed species possess more glial cells in the central nervous system 
than less developed ones. While the Drosophila nervous system is composed of 
10-20% of glial cells, at least 50% of the cells in the human CNS are glial cells. 
This suggests, that more complex neuronal processes are only possible in the 
presence of a higher number of glial cells. Three main classes of glial cells with 
different functions are found in the vertebrate nervous system. These cells 
comprise astrocytes, oligodendrocytes and microglia. Oligodendrocytes and 
Introduction  
 18 
astrocytes, both designated as macroglial, originate from the neuroepithelium, 
whereas microglia cells derive from mesodermal tissue (65).  
 
 
 
Figure 1.6.2: Gliogenesis in embryonic vertebrates (modified from (65)). 
 
During embryonic gliogenesis, at the time neurogenesis begins, self-renewing 
neuroepithelial cells at the ventricular surface differentiate into radial glial cells 
(RGC). On the one hand, RGC are able to generate intermediate progenitor cells 
(IPCs) on the other hand they produce oligodendrocytes precursor cells (OPCs). 
OPCs in turn generate oligodendrocytes. Additionally, RGC can become 
astrocytes or IPCs that expand in number before giving rise to astrocytes (Figure 
1.6.2) (65).  
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1.7 Aims of the study 
 
Molecular pathomechanisms leading to the formation of intractable epilepsy-
associated gangliogliomas are still unclear. Previous studies suggest these tumors 
to be highly complex and multifactorial diseases of cortical development (66-68). 
LRP12, a gene abundantly expressed during murine corticogenesis (37), 
combines distinct characteristics, supporting the hypothesis of LRP12 being a key 
regulator for the pathogenesis of gangliogliomas. LRP12’s function as a tumor 
suppressor molecule (38) as well as its low abundance in gangliogliomas (26) hint 
towards a contribution to the proliferative astroglial phenotype of these tumors. 
Additionally, as gangliogliomas are believed to origin from maldevelopmental 
precursor cells (18), less LRP12 amounts during embryogenesis possibly foster 
the formation of the dysplastic neuronal phenotype observed in these neoplasms. 
The objective of this study is to thoroughly investigate LRP12’s contribution to the 
manifestation of gangliogliomas. Therefore, the following core questions were 
addressed: 
A) Is there a significantly increased abundance of a certain SNP in the LRP12 
promoter region of ganglioglioma patients? 
B) Do such SNPs have a biological impact on LRP12 promoter activity in vitro? 
C) Do reduced LRP12 mRNA levels lead to a lack of LRP12 protein in 
gangliogliomas? 
D) Does a lack of LRP12 increase growth kinetics of primary astrocytes in vitro? 
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E) Does a lack of LRP12 in primary cortical neurons cause an aberrant neuronal 
arborization in vitro? 
F) Does a depletion of LRP12 in embryonic mice lead to an aberrant neuronal 
migration during corticogenesis including a dysplastic epileptogenic lesion or 
tumor? 
G) Furthermore, detailed characterizations of LRP12 expression levels during 
embryogenesis and in adult mice as well as analyses of post-translational 
modifications and LRP12’s subcellular localization are carried out.  
Answering the questions posed above may contribute to a better understanding of 
the molecular pathomechanisms leading to the manifestation of gangliogliomas. 
Hopefully, this study will aid the development of novel therapy approaches for 
pharmacoresistant epilepsies in the future. 
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2 Materials 
 
 
2.1 Equipment 
 
The following equipment (Table 2.1.1) was used. 
 
Table 2.1.1: Equipment. 
 
Application Model Company 
Acrylamid electrophoresis 
system 
Mini-PROTEAN 3 
Electrophoresis 
System 
BioRad 
Agarose electrophoresis 
system 
SUB-CELL GT BioRad 
Analytical balance BP210S Satorius 
Autoclave Varioklav 75T H + P 
Balance SBC53 SCALTEC 
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Capillary Sequencer 3130/xl/Genetic 
Analyzer 
Applied Biosystems 
Cell culture dishes  Greiner 
Cell culture hood MSC-Advantage Thermo Scientific 
Centrifuge 1-15K Sigma 
Centrifuge 5415C Eppendorf 
Centrifuge Micro 22 R Hettich 
Centrifuge Avanti J-20 Beckman Coulter 
Confocal laser scanning 
mircroscope 
A1/Ti-E Confocal Nikon 
Electroporator  CUY21SC BTX Harvard Apparatus 
Glass capillaries  Drummond Scientific 
Gel documentation system Alphamanager Alpha Innotech 
Incubator T6 Heraeus Instruments 
Infrared imaging system Odyssey Li-cor 
Microinjector  Picospritzer II General Valve 
Corporation 
Microscope Axio Observer A1 Zeiss 
Mikrotom HM 335 E Thermo Scientific 
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PCR-Cycler MY Cycler  BioRad 
PCR-Cycler T3 Thermocycler Biometra 
Real time PCR (Taqman) 9700HT ABI Prism 
pH-meter HI 9025 HANNA Instruments 
Photometer BIO Eppendorf 
Spectrophotometer NanoDrop2000 Thermo Scientific 
Thermo shaker MK13 HCL 
Transfer System Mighty Small 
Transphor/Hoefer 
TE22 
Amersham 
Ultrasonicator UP50H Hilscher 
Vibratome HM 650 Thermo Scientific 
Vortex Vortex-Genie 2 Scientific Industries 
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2.2 Material and Reagents 
 
The following materials and reagents were used. 
 
2.2.1. Antibodies 
 
The following antibodies were used for western blot analyses (WB) and 
immunohistochemical stainings (IHC). 
 
Table 2.2.1: Primary antibodies. 
 
Antibody Assay Dilution Company 
-Tubulin WB 1:10000 Abcam 
-Actin WB 1:5000 Abcam 
CUX1 IHC 1:200 Santa Cruz 
GAPDH WB 1:500 Novus Biologicals 
GFAP IHC 1:350 Sigma-Aldrich 
GM130 IHC 1:500 BD Bioscience 
HA WB 1:1000 Covance 
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hrGFP (monoclonal) IHC 1:5000 Stratagene 
hrGFP (polyclonal) IHC 1:5000 Stratagene 
LRP12 WB/IHC 1:350 Sigma-Aldrich 
LRP12 IHC 1:350 Biobryt 
NeuN IHC 1:500 Millipore 
PSD95 IHC 1:500 Upstate 
Synapsin I IHC 1:500 Synaptic Systems 
 
 
Table 2.2.2: Secondary antibodies. 
 
Antibody Assay Dilution Company 
Anti-mouse FITC IHC 1:400 Jackson Research 
Anti-rabbit Cy3 IHC 1:400 Jackson Research 
Anti-mouse Cy5 IHC 1:400 Jackson Research 
IRDye anti-mouse 680 nm WB 1:25000 Li-Cor 
IRDye anti-rabbit 800 nm WB 1:25000 Li-Cor 
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2.2.2. Cell culture media 
 
Table 2.2.3: Cell culture reagents. 
 
Reagent Company  
Dulbecco’s Modified Eagle Medium (DMEM) Gibco  
Basal Medium Eagle (BME) Gibco 
Fetal calf serum (FCS) Gibco 
Hank’s Balanced Salt Solution (HBSS) Gibco 
HAT Supplement Gibco 
Opti-MEM Gibco  
Phosphate buffered saline (PBS) Gibco 
Penicillin-Streptomycin (Pen Strep) Gibco 
Glucose Life Technologies 
B27 Life Technologies 
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2.2.3. Chemicals 
 
Chemicals were ordered from standard sources (Roth, Sigma-Aldrich, Merck). 
 
Table 2.2.4: Chemicals. 
 
Chemical Company 
Acrylamide Roth 
Agarose Roth 
Ampicillin Roth 
Bovine serum albumin (BSA) Roth 
Cold water fish skin gelatine Sigma-Aldrich 
Complete Protease Inhibitor Cocktail Tablets Roche 
4’, 6-Diamidin-2-phenylindol (DAPi) Life Technologies  
Fast Green Sigma 
Fetal calf serum (FCS) Gibco 
Ketamine (Ketavet) Pfizer 
Mowiol 4-88 Roth 
Normal goat serum (NGS) Gibco 
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NP40 Sigma-Aldrich 
Paraformaldehyde (PFA) Merck 
Pentylenetetrazol Sigma-Aldrich 
Triton X-100 Sigma-Aldrich 
Vectashield mounting medium Vector Laboratories 
Xylazine (Rompun) Bayer 
 
 
2.2.4. Diverse materials 
 
Table 2.2.5: Diverse materials. 
 
Material Company 
Blotting paper Whatman, GE Healthcare 
Nitrocellulose membrane (Protran 0.4 mm) Whatman, GE Healthcare 
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2.2.5. Enzymes 
 
Table 2.2.6: Enzymes. 
 
Enzyme Company 
BamHI Thermo Scientific 
HindIII Thermo Scientific 
MluI Thermo Scientific 
PNGase F New England Biolabs 
Platinum®Taq Life Technologies 
Trypsin Gibco 
T4 Ligase Thermo Scientific 
 
 
2.2.6. Kits 
 
Table 2.2.7: Kits. 
 
Kit Company 
BigDye Terminator v3.1cycle Sequencing kit Applied Biosystems 
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CyQUANT® Cell Proliferation Assay Life Technologies 
DNA Clean and Concentration kit Zymo Research 
Dual Luciferase Reporter System Promega 
Dynabeads®mRNA DIRECT™Micro Kit Life Technologies 
GeneJET Plasmid Miniprep kit Thermo Scientific 
Lipofectamine 2000 Life Technologies 
QuickChange II XL Site Directed Mutagenesis 
kit 
Stratagene 
PRISM Big Dye Terminator (Sequencing) Applied Biosystems 
Pure link Midi kit (DNA purification) Life Technologies 
RevertAid H Minus First Strand cDNA 
Synthesis Kit 
Thermo Scientific 
SYBR ® Green RT-PCR Mix Applied Biosystems 
Zymoclean Gel DNA recovery kit Zymo Research 
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2.3 Oligonucleotides 
 
2.3.1. Cloning 
 
Table 2.3.1: Oligonucleotides for the generations of shRNAs against murine Lrp12 
mRNA. 
 
Oligo  5’- Sequence-3’ Vector 
shmLRP12
_749 
sense GATCTTTGACAGTGAGCGACGACATGCG
GACAATGGTTAATAGTGAAGCCACAGAT
GTATTAACCATTGTCCGCATGTCGGTGC
CTACTGCCTCGGA 
pAM/U6-
shRNA-
CBA-hrGFP 
shmLRP12
_749 
antisense AGCTCCGAGGCAGTAGGCACCGACATG
CGGACAATGGTTAATACATCTGTGGCTT
CACTATTAACCATTGTCCGCATGTCGTC
GCTCACTGTCAAA 
pAM/U6-
shRNA-
CBA-hrGFP 
shmLRP12
_869 
sense GATCTTTGACAGTGAGCGCCGTGTCTCC
CTGAGTCCTTAATAGTGAAGCCACAGAT
GTATTAAGGACTCAGGGAGACACGTTGC
CTACTGCCTCGGA 
pAM/U6-
shRNA-
CBA-hrGFP 
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shmLRP12
_869 
antisense AGCTTCCGAGGCAGTAGGCAACGTGTCT
CCCTGAGTCCTTAATACATCTGTGGCTT
CACTATTAAGGACTCAGGGAGACACGGC
GCTCACTGTCAAA 
pAM/U6-
shRNA-
CBA-hrGFP 
shmLRP12
_64 
sense GATCTCCGGACAGATAAGAGTACATTCT
CGAGAATGTACTCTTATCTGTCCGGA 
pAM/U6-
shRNA-
CBA-hrGFP 
shmLRP12
_64 
antisense GCTTCCGGACAGATAAGAGTACATTCTC
GAGAATGTACTCTTATCTGTCCGGA 
pAM/U6-
shRNA-
CBA-hrGFP 
 
 
Table 2.3.2: Primers used for constructs employed in luciferase assays. 
 
Gene  5’- Sequence-3’ Vector 
hLRP12 fw GCGACGCGTCCAAGTTGTCAGCTT
CAGA 
pGL3-Basic 
hLRP12 rv GCGACGCGTAAGTCAGGGGAGACC
ACGAAC 
pGL3-Basic 
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Table 2.3.3: Primers used for site-directed mutagenesis. 
 
Template  5’- Sequence-3’ Base 
exchange 
pGL3-
Basic_hLRP12 
fw GTCTACCTCCAGCTCCTCCTCCCTC
CTCC 
T->C 
pGL3-
Basic_hLRP12 
rv GGAGGAGGGAGGAGGAGCTGGAG
GTAGAC 
T->C 
 
 
Table 2.3.4: Primers used for RT-PCR. 
 
Gene  5’- Sequence-3’ 
mLrp12 fw GCTCCTCCCTCATATGGACA 
mLrp12 rv AGATCGGACAGCTAGCCTCA 
mSynaptophysin fw TTCAGGACTCAACACCTCGGT 
mSynaptophysin rv CACGAACCATAGGTTGCCAAC 
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Table 2.3.5: Sequencing primers. 
 
Template  5’- Sequence-3’ 
pAM/U6-shRNA-
CBA-hrGFP 
fw TACGATACAAGGCTGTTAGAGAG 
pGL3-Basic fw CTAGCAAAATAGGCTGTCCC 
pGL3-Basic rv CTTTATGTTTTTGGCGTCTTCCA 
 
 
2.4 Vectors and vector construction 
 
2.4.1 Multiple cloning sites (MCS) 
 
pAM/U6-shRNA-CBA-hrGFP: 
 
 
 
Figure 2.4.1: Multiple cloning site of pAM/U6-shRNA-CBA-hrGFP. 
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pGL3-Basic: 
 
 
 
Figure 2.4.2: Multiple cloning site of pGL3-Basic (purchased from Promega). 
 
 
2.4.2 Generated constructs 
 
Table 2.4.1: Generated constructs. 
 
Name Insert Template Vector Enzymes 
pAM/U6- 
shmLRP12_749-
CBA-hrGFP 
shmLRP12_749 oligo pAM/U6-
shRNA-
CBA-hrGFP 
BamHI 
HindIII 
pAM/U6- 
shmLRP12_869-
CBA-hrGFP 
shmLRP12_869 oligo pAM/U6-
shRNA-
CBA-hrGFP 
BamHI 
HindIII 
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2.4.3 Plasmids obtained from other labs 
 
pAM/U6-shRNA-CBA-hrGFP 
pCMV_mLRP12_HA  
pCDNA3.1_STAT5a*6VT 
pCAG _RFP 
 
 
 
 
pAM/U6- 
shmLRP12_64-
CBA-hrGFP 
shmLRP12_64 oligo pAM/U6-
shRNA-
CBA-hrGFP 
BamHI 
HindIII 
pGL3-
Basic_hLRP12_
WT 
Promoter_hLRP12_
WT 
blood DNA pGL3-Basic MluI 
HindIII 
pGL3-
Basic_hLRP12_
SNP 
Promoter_hLRP12_ 
SNP 
pGL3-
Basic_hLR
P12_WT 
pGL3-Basic  
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2.5 Biological materials 
 
2.5.1 Surgical specimens  
 
Ganglioglioma biopsy samples were collected from patients with chronic 
pharmacoresistant temporal lobe epilepsy (TLE) in the Epilepsy Surgery Program 
at the Bonn University. For immunohistochemical analyses a total number of 13 
surgical specimens were available (Table 2.5.1). Surgical removal of the 
epileptogenic area was carried out after standardized presurgical evaluation 
consisting of non-invasive and invasive procedures (69). In order to minimize 
structural variability, patients were carefully matched regarding clinico-
epidemiological criteria. Each specimen has been subjected to standardized 
neuropathological evaluation by two independent neuropathologists and classified 
according to the World Health Organization classification of tumors (70). 
 
Table 2.5.1 Overview on clinical parameters of patients included in this study. 
 
ID Age 
at 
OP 
Lesion Sex Seizure 
type 
Disease 
duration 
Seizure 
frequency/ 
month 
Age at 
disease 
onset 
Medication 
at OP 
1 20 GG M CPS with 
sGTCS 
16 1 4 OXC 
2 30 GG F SPS, CPS 26 5 4 CBZ 
3 9 GG M CPS 3 4 6 OXC 
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4 37 GG F SPS, CPS 
with 
sGTCS 
31 10 6 LTG, LEV 
5 23 GG M SPS, CPS 16 12 7 OXC 
6 36 GG F SPS 13 8 23 LTG, VPA 
7 14 GG M SPS, CPS 
with 
sGTCS 
12 30 2 TPM, 
CBZ, LTG 
8 23 GG F SPS, CPS 
with 
sGTCS 
2 2 21 LTG 
9 29 GG M SPS, CPS 4 60 25 LEV 
10 3 GG M SPS, CPS 3 15 0 OXC 
11 16 GG F SPS, CPS 7 30 9 LEV 
12 13 GG F SPS, CPS 12 150 1 VPA 
13 10 GG F SPS, CPS 3 n.k. 7 OXC 
 
ID, identification number; GG, ganglioglioma (WHO grade I); F, female; M, male; 
SPS, simple partial seizures; CPS, complex partial seizures; sGTCS, secondary 
generalized tonic clonic seizures; n.k., clinical parameter is not known. Disease 
duration at time of surgery and age at onset of epileptic seizures is given in years; 
seizure frequency is given in events per month. CBZ (Carbamazepine); LEV 
(Levetiracetam); LTG (Lamotrigine); TPM (Topiramate); OXC (Oxcarbazepine); VPA 
(Valproate). 
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2.5.2 Cell lines  
 
HEK293T cells, human embryonic kidney cells  
 
NG108-15 cells, hybrid of murine neuroblastoma and rat glioma cells 
 
Primary murine neurons from E19 C57BL/6 mice 
 
Primary murine glial cells from P1 C57BL/6 mice 
 
 
2.6 Software 
 
Table 2.6.1: Software. 
 
Program Source 
CpGPlot http://emboss.bioinformatics.nl/cgi-bin/emboss/cpgplot 
COMET http://zlab.bu.edu/~mfrith/comet/form.html 
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Eponine http://www.molecularstation.com/bioinformatics/link/detail/link-
493.htm 
Fiji http://www.fiji.gov.fj/ 
ImageJ http://rsb.info.nih.gov/ij/ 
Lasergene 8 
software SeqMan 
DNASTAR 
PoSSuMsearch http://bibiserv.techfak.uni-bielefeld.de/possumsearch/ 
AIDA Raytest 
 
 
2.7 Bioinformatic analyses 
 
To identify potential promoter regions upstream of the LRP12 gene, software tools 
CpGPlot (71), COMET (72), and Eponine (73) were used. In order to detect 
potential transcription factor (TF) binding sites, the tool PoSSuMsearch (74) using 
position-specific-scoring matrices from the TRANSFAC database (75, 76) was 
applied to the potential promoter regions. For filtering the potential TF binding 
score a matrix similarity score (MSS) of 70% was applied. 
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3 Methods 
 
All methods were performed following standard procedures (Current Protocols in 
Molecular Biology) if not noted otherwise.  
 
3.1 Molecular biological methods 
 
3.1.1 mRNA isolation and cDNA synthesis 
 
Total mRNA was isolated from cells using the Dynabeads®mRNA DIRECT™Micro 
Kit according to the manufacturer’s (Life Technologies) instructions. Samples were 
stored at -80°C. Reverse transcription was carried out using RevertAidH Minus 
First Strand cDNA Synthesis Kit with oligo dT primers. 5μg of total mRNA was 
used for every reverse transcription reaction. The cDNA synthesis reaction was 
carried out according to the manufacturer’s (Thermo Scientific) instructions. cDNA 
samples were stored at -20°C. 
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3.1.2 PCR protocols 
 
Standard PCR protocol 
 
All standard PCR reactions were carried out according to the conditions shown in 
table (3.1.1). 
 
Table 3.1.1: Standard PCR protocol. 
 
Step Temperature Time Cycle 
1 94°C 10min  
2 94°C 30sec  
3 55°C 40sec  
4 68°C Xkb x 1min 33 cycles steps 2-4 
5 68°C 10min  
6 4°C   
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Site-directed mutagenesis was carried out according to the conditions shown in 
table (3.1.2). 
 
Table 3.1.2: PCR protocol for site-directed mutagenesis. 
 
Step Temperature Time Cycle 
1 95°C 1min  
2 95°C 50sec  
3 60°C 50sec  
4 68°C Xkb x 1min 18 cycles steps 2-4 
5 68°C 7min  
6 4°C   
 
 
General amplification procedure 
For amplifications genomic blood DNA, Platinum®Taq and the standard PCR 
protocol were used. For site-directed mutagenesis pGL3-Basic_hLRP12_WT 
plasmid was employed as template for PCR reaction. 
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3.1.3 Real-time PCR 
 
Real-time PCR was carried out using the SYBR Green PCR kit following the 
manufacturer’s (Applied Biosystems) instructions. Relative quantification of target 
gene expression and PCR efficiency were performed using Synaptophysin as 
internal reference gene. The expression of the genes was calculated via the 
formula (ProbeCT)-(SynaptophysinCT) = z; sample expression = 2-z. 
 
 
3.1.4 Vector generation 
 
For Luciferase reporter gene vector generation DNA fragments were amplified 
from genomic blood DNA using PCR. DNA fragments were purified (DNA Clean 
and Concentration kit) and cut with MluI and HindIII. Afterwards, amplified DNA 
was separated on an agarose gel and the band of interest was cut out and purified 
(Zymoclean Gel DNA recovery kit). PGL3-Basic vector was digested with MluI and 
HindIII enzymes and purified (DNA Clean and Concentration kit). The ligation 
reaction was carried out at 37°C for 1h. For generation of shRNA constructs 
pAM/U6-shRNA-CBA-hrGFP vector was cut with BamHI and HindIII and purified 
(DNA Clean and Concentration kit). Oligo annealing was accomplished as follows: 
Sense and antisense oligos (50μM each) were incubated with annealing puffer 
(10mM Tris pH 8.0, 50mM NaCl, 1mM EDTA) at 95°C for 10min, for 10min at 
70°C and subsequently slowly cooled off to room temperature. Annealed oligos 
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were ligated into the pAM/U6-shRNA-CBA-hrGFP vector by incubating for 1h at 
37°C. 
 
 
3.1.5 Site-directed mutagenesis 
 
Primers were designed according to the manufacturer’s (Stratagene) 
recommendations. Mutations were introduced using the QuickChange II XL Site-
directed Mutagenesis Kit using standard conditions as advised by the 
manufacturer (Stratagene).  
 
 
3.1.6 Sequencing 
 
For sequencing of plasmid DNA BigDyeTerminator v3.1 cycle sequencing kit and 
a template specific primer were used. Sequencing PCR reactions were purified 
(DNA Clean and Centration kit) and sequencing was carried out using a capillary 
sequencer. Analyses of the sequencing results were accomplished using SeqMan 
software.  
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3.2 Biochemical methods 
 
3.2.1 Western blot analyses 
 
Proteins from transfected HEK293T cells were extracted with PBS+10mM EDTA 
buffer. Proteins from whole brain lysates of E13.5 and adult mice (C57BL/6 mice) 
were extracted with NP40 buffer. N-deglycosylation was performed with PNGase F 
following the manufacturer’s (New England Biolabs) specifications. Different 
regions of adult mice brain were lysed with NP40 buffer. Equal amounts of protein 
extracts (50.0g/sample) were separated by SDS-PAGE and blotted to 
nitrocellulose over night (45.0mA). After blocking with 5% cold fish gelatine 
solution, membranes were incubated either with mouse anti--Actin (Abcam), 
mouse anti--Tubulin (Abcam) or mouse anti GAPDH (Novus Biologicals) for 
control and rabbit polyclonal anti-LRP12 antibody (Sigma-Aldrich) followed by 
decoration with fluorescent labeled IRDye anti-mouse 680 nm or IRDye anti-rabbit 
800 nm IgG (Li-Cor), respectively. The bound complexes were detected with the 
Odyssey system. 
 
 
3.2.2. Immunohistochemical stainings 
 
For co-immunofluorescence stainings, paraffin embedded ganglioglioma 
specimens with HE-staining identified adjacent non-tumor control tissue were 
microwaved for permeabilization in citric buffer for 10min. Slices were blocked with 
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10% FCS, 1:100 NGS in PBS for 2h at 37°C. Antibodies against LRP12 
(Stratagene) and NeuN (Millipore) or LRP12 (Stratagene) and GFAP (Sigma-
Aldrich) were incubated over night at 4°C. After washing 3 times with PBS 
secondary antibodies against anti-mouse and anti-rabbit IgG (Jackson Research) 
were incubated for 2h at room temperature. Subsequently, slices were washed 
three times with PBS at room temperature. Co-immunofluorescence stainings of 
vibratome slices (40.0m) of electroporated and perfused brains were made as 
follows: Slices were permeabilized in 5% BSA, 3% Triton-X100 in PBS for 1 hour 
at room temperature. Antibodies against hrGFP (Stratagene) (polyclonal) and 
NeuN (Millipore) or hrGFP (Stratagene) (monoclonal) and LRP12 (Biobryt) were 
applied over night at 4°C. After washing 3 times with PBS, the secondary 
antibodies against anti-mouse and anti-rabbit IgG (Jackson Research) were 
incubated for 2h at room temperature. Subsequently, slices were washed three 
times with PBS at room temperature. For co-immunofluorescence analysis of 
primary DIV14 cortical neurons, cells were fixed with 4% PFA for 15min, washed 
three times with PBS and treated with blocking solution (0.1% Triton-X, 1% FCS, 
10% BSA in PBS) for 1h. Neurons were incubated with antibodies against 
Synapsin I (Synaptic Systems) and LRP12 (Stratagene) or PSD95 (Upstate) and 
LRP12 (Stratagene) or GM130 (BD Bioscience) and LRP12 (Stratagene) or hrGFP 
(Stratagene) (polyclonal) over night at 4°C. Subsequently, cells were washed three 
times with PBS at room temperature. Secondary antibodies against anti-mouse 
and anti-rabbit IgG (Jackson Research) were incubated for 45min at room 
temperature. Afterwards, cells were washed three times with PBS at room 
temperature. 
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3.3 Cell culture 
 
HEK293T cells were cultured in DMEM supplemented with 10% FCS and 1% Pen 
Strep at 37°C in 5% CO2. Transfection of HEK293T cells for western blot analysis 
was carried out using Lipofectamine following the manufacturer’s (Life 
Technologies) instructions. NG108-15 neuroblastoma cells were grown in DMEM 
supplemented with 10% FCS, 1% Pen Strep and 10% HAT at 37°C in 5% CO2. 
Transfection of NG108-15 cells was carried out using Lipofectamine according to 
the manufacturer’s protocol (Life Technologies). Primary cortical neurons were 
prepared from E19 mouse brains (C57BL/6 mice) (77). Neurons were plated on 
poly-D-lysine coated (0.01%) 24 well plates at a density of 60.000 cells/well and 
were grown in Basal Medium Eagle. At DIV0 cortical neurons were transduced 
with recombinant adeno-associated virus (rAAV) particles serotype 1/2. Primary 
astrocytes were prepared from cortices of P1 mice (C57BL/6 mice). First, cortices 
were opened with forceps. Small cortex pieces were washed three times with 
HBSS. Trypsin was added and cells were incubated at 37°C for 20 minutes. 
Subsequently, cells were washed 3 to 5 times with HBSS and then treated with 
1mg/ml DNase. Afterwards astrocytes were singularized using a syringe and a cell 
sieve. Cells were grown at 37°C in 5% CO2 in DMEM for 14 days before replating. 
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3.3.1 In vitro assays 
 
3.3.1.1 Cell proliferation assays 
 
Primary astrocytes were plated in 96 well plates at a density of 1750 cells/well. On 
the day after plating, glial cells were transduced with rAAV particles. Cells were 
harvested 3, 4, 5 and 6 days after transduction. CyQUANT® Cell Proliferation 
assays were carried out according to the manufacturer’s  (Life Technologies) 
protocol. 
 
 
3.3.1.2 Luciferase assays 
 
The Dual Luciferase Reporter System was used according to the manufacturer’s 
(Promega) instructions. Renilla luciferase was used to normalize the transfection 
efficiency. Renilla and Firefly Luciferase activity were measured using the 
Glowmax Luminometer system. For each well of the 48 well plate 50.0ng 
luciferase reporter plasmid, 12.5ng pRL-SV40 (purchased from Promega) and 
10.0ng pGLbasic (purchased from Promega) were transfected. For transfections 
with STAT5a*6V 10.0 ng of the overexpression plasmid were added instead of the 
pGLbasic plasmid. NG108-15 cells were harvested 48 h after transfection. 
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3.3.2 rAAV virus production 
 
80% confluent HEK293T cells were plated into a 10cm dish. 24h later, cells were 
transfected with calcium phosphate as described previously (78). For each dish 
5.5g AAV construct, 11.0g pFdelta6 plasmid, 2.64g pRV1 plasmid and 2.75g 
pH21 plasmid were transfected. 72h later cells were harvested in DMEM and lysed 
by 3 times freeze-and- thawing. 
 
 
3.3.3 Quantification of LRP12 mRNA/LRP12 knockdown efficiency in 
vitro 
 
For LRP12 knockdown quantification in HEK293T cells, cells were co-transfected 
with 300ng of LRP12 overexpression plasmid with either 1800ng of the U6 control 
vector (pAM/U6-shRNA-CBA-hrGFP) or the respective shRNA constructs. Cells 
were harvested 72 hours after transfection and applied to western blot analysis. 
Quantification of LRP12 knockdown efficiency was carried out using AIDA 
software. To determine LRP12 knockdown efficiency in neurons, cells were 
transduced with respective rAAV virus particles on day DIV0 and harvested on 
DIV14. QRT-PCR, Western blot analysis and knockdown quantification was 
carried out as described above. 
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3.4 In utero electroporation studies 
 
3.4.1 In utero electroporation 
 
Timed pregnant mice (C57BL/6 mice) with embryos being E16 were anesthetized 
with ketamine/xylazine (100mg/kg and 10mg/kg respectively). The uterine horns 
were exposed to 2μl of plasmid DNA of pCAG-red fluorescent protein (RFP) 
(1.5μg/μl) and U6-hrGFP (1.5μg/μl) with Fast Green (2mg/ml) or to 2μl (1.5μg/μl) 
shRNAMix (sh749, sh869 and sh64 with a concentration of 1.5μg/μl each) 
constructs with Fast Green (2mg/ml). Plasmids were injected into the lateral 
ventricle of each embryo with a pulled glass capillary and a microinjector. 
Electroporation was then conducted by discharging a 4000μF capacitor charged to 
50V with a CUY21SC electroporator. Five electric pulses (5ms duration) were 
delivered at 950ms intervals with electrodes (7mm for mice) placed to target 
cortical ventricular progenitors. Embryos were then allowed to develop completely. 
At day P21, animals were sacrificed. The positions of electroporated cells were 
analyzed by immunohistochemical stainings against DAPI/NeuN and hrGFP. 
Cortical quantification was performed with the Fiji software on coronal sections 
(40μm) located in the dorso-lateral neocortex. Relative positions of transfected 
cells were determined by DAPI/NeuN stainings and calculated in percentage 
compared to the total number of electroporated cells. Analyses of neuronal 
migration were conducted on coronal sections (40μm) with Fiji software. The 
number of electroporated cells in the cortex was counted, and the percentage of 
electroporated cells in upper or lower external granular layer was calculated. 
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3.4.2 Analysis of PTZ induced seizure sensitivity 
 
Developing mice were subjected to in utero electroporation as described above. 
Adult animals (P40) were weighed and injected intraperitoneally with 
Pentylenetetrazole (PTZ) as described in detail before (79). Briefly, PTZ was 
solved in PBS at a concentration of 6mg/ml. All mice were injected with PTZ at a 
dose of 10mg/kg every 10min until their first occurring focal or generalized seizure. 
For characterization of PTZ-induced seizures, the time until primary seizure 
activity, PTZ dosage as well as the nature of seizure severity (focal or generalized) 
were analyzed by independent observers blinded to the experimental groups. 
Subsequently, animals were sacrificed for neuropathological analyses via PFA 
heart perfusion. 
 
 
3.4.3 Quantification of LRP12 knockdown efficiency in vivo 
 
Vibratome slices of with shRNAs electroporated mice were co-
immunohistochemically stained with antibodies against hrGFP (Stratagene) 
(monoclonal) and LRP12 (Biobryt). Confocal images at a high magnification (600x) 
of electroporated and adjacent non-electroporated neurons were obtained. Cell 
fluorescence intensity as a measure for LRP12 levels was quantified using Fiji 
software. 
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3.5 Image analysis and quantification 
 
(a) Digital images of single transduced neurons (at high magnification, 400x) were 
subjected to morphometric analyses and quantification using Fiji software. For 
‘Sholl analysis’, each branch was traced from branching point to the tip. The 
concentric rings with 25.0μm intervals were overlaid on each traced image, and 
the numbers of neurite branch intersections were counted within each circle (80). 
All quantifications were performed by investigators ‘blinded’ to the experimental 
condition. (b) Digital images of co-immunohistochemically stained ganglioglioma 
samples were taken at a 200x magnification. For semi-quantitative analysis of 
LRP12 expressing elements in GG and control tissue, cells were categorized 
semiquantitatively as low-, medium- and strong expressing neurons and glial cells. 
Neurons and glial cells in an area of 664 x 500m were counted, categorized and 
the proportion of low-, medium- and strong expressing neurons and glial cells was 
calculated. (c) With respect to analysis of mouse brains after intraventricular in 
utero electroporation, we examined brains, which were electroporated with LRP12-
targeted shRNA versus control vectors, by taking digital images of co-
immunohistochemically stained vibratome (40.0m) slices at a 50x magnification. 
DAPi and NeuN IHCs were used to define cortical layers. Confocal images of 
Synapsin I/LRP12 and PDS95/LRP12 co-immunostained neurons were examined 
under the microscope at a 600x magnification. 
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3.6 Statistical analysis 
 
Fisher’s exact test was applied to test differences between the severity of PTZ-
induced seizures between shRNA treated and control animals. Analysis of 
variance t-test was used as indicated to test the statistical significance for 
semiquantification of LRP12 expressing cell components, ‘Sholl analysis’, cell 
proliferation assays and analysis of dosage and time dependent sensitivity of PTZ-
induced seizure. One-way ANOVA was carried out for luciferase assays and the 
evaluation of the migrating behavior of electroporated neurons. All standard errors 
are indicated as the ‘standard error of the mean’ (SEM).  
 
 
Results 
 55 
 
4 Results 
 
4.1 Temporal and regional expression patterns of LRP12 and 
posttranslational modifications  
 
Murine Lrp12 is a homologue of C. elegans’ gene mig-13, which holds a key 
regulator function for accurate neuronal migration (37, 53, 81). LRP12 is highly 
expressed in a subpopulation of preplate neurons during rodent corticogenesis 
(37). However, the expression of LRP12 during embryogenesis and in adult 
mouse brain has not been thoroughly analyzed. 
 
 
4.1.1 Test for -LRP12 antibody specificity 
 
For validating -LRP12 antibody specificity, immunoblotting analyses with 
HEK293T cell homogenates overexpressing LRP12_HA and native cell lysates 
were carried out. Staining with an antibody against LRP12 reveals two bands at 
110kDa and 92kDa respectively in cells overexpressing LRP12_HA. In contrast to 
that native HEK293T cells exhibit only one band at 92kDA. Membrane treatment 
with an antibody against the HA epitope discloses a specific LRP12_HA band at 
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110kDa, whereas no antigen-HA antibody reaction was detectable in non-
transfected HEK cells (Figure 4.1.1).  
 
 
 
Figure 4.1.1: Western blot analyses of HEK293T cells overexpressing murine 
LRP12_HA and non-transfected HEK cells. Membranes were treated with antibodies 
against LRP12 or HA-tag. A specific LRP12_HA band was detectable with 
antibodies against LRP12 and HA-tag at 110kDa in HEK cells overexpressing 
LRP12_HA. -Actin served as loading control.  
 
 
4.1.2 Expression of LRP12 in embryonic and adult mouse brain 
 
Initially, expression of LRP12 in developing and adult brain was investigated by 
immunoblotting analysis of whole brain lysates. As control for antibody specificity a 
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protein homogenate from HEK293 cells overexpressing murine LRP12 was 
included in the study. Immunoblotting with an antibody against LRP12 revealed 
the specific LRP12 band at 110kDa in the embryonic and adult mouse brain as 
well as in the HEK293T cell homogenate, showing LRP12 expression in 
embryonic and adult brain (Figure 4.1.2).  
 
 
 
Figure 4.1.2: Immunoblot analysis of whole mouse brain homogenates from 
different stages of life. Treatment with an antibody against LRP12 reveals LRP12 
expression in E13.5 as well as adult brains. To control for antibody specificity 
LRP12 was overexpressed in HEK293T cells (control). GAPDH served as loading 
control. 
 
 
4.1.3 Spatial expression of LRP12 in rodent brain 
 
To investigate the regional distribution of LRP12, homogenates from various adult 
mouse brain regions were analyzed by immunoblotting. The specific LRP12 band 
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at 110kDa is present in all examined adult brain regions but exhibits considerable 
differences in regional abundance (Figure 4.1.3 A, B). The expression of LRP12 is 
highest in medulla, olfactory bulb as well as temporal and frontal cortex. LRP12 
levels of striatum and cerebellum are moderate, whereas the abundance in spinal 
cord, thalamus and hippocampus is only low.  
 
 
 
Figure 4.1.3: LRP12 expression in distinct brain regions of adult mice. (A) 
Homogenates of various brain regions, i.e. spinal cord, medulla, cerebellum, 
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thalamus, hippocampus, striatum, temporal cortex, frontal cortex and olfactory bulb 
were prepared from adult mouse brain and analyzed by immunoblotting with 
antibodies against LRP12 and GAPDH. (B) LRP12 immunoblot signal was quantified 
in distinct brain regions of adult mice with AIDA software. To control for loading 
differences the LRP12 signal was normalized to GAPDH. Expression levels are 
depicted relative to LRP12 expression in the medulla by setting medulla’s LRP12 
expression as one. 
 
 
4.1.4 Posttranscriptional modifications of LRP12 
 
Members of the LRP receptor family have been described as regulated by 
glycosylation (82). To investigate whether LRP12 is modified via posttranslational 
glycosylation, HEK293T cells overexpressing LRP12 were exposed to PNGase F, 
an enzyme that cleaves N-glycosylated polysaccharides from proteins. The results 
of the immunoblotting analysis indicate that following treatment with this enzyme; 
LRP12 motility is altered, suggesting receptor glycosylation (Fig. 4.1.4). 
 
 
 
Figure 4.1.4: Treatment of LRP12 overexpressed in HEK293T cells with PNGase F, 
an enzyme, which cleaves N-glycosylated sugars. Cell extracts were incubated with 
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or without PNGase F for 1h at 37°C prior SDS-Page and immunoblot analysis. After 
PNGase F treatment the apparent molecular weight of LRP12 is decreased 
reflecting N-glycosylation of LRP12. 
 
 
4.2 Subcellular localization of LRP12 in neurons 
 
4.2.1 LRP12 is localized in the soma and neurites of neurons  
 
In order to unravel the subcellular localization of LRP12, i.e. a putative 
transmembrane protein (43), co-immunohistochemical stainings of LRP12 and 
either the presynaptic marker protein Synapsin I or the postsynaptic marker 
protein PSD95 were performed in DIV14 primary cortical neurons. LRP12 was 
found to be present in the soma and dendritic compartment of neurons. There it is 
expressed in a punctate fashion. In contrast to that, it is apparently absent from 
the nucleus (Figure 4.2.1). Despite its presence in the axon and the dendrites no 
co-labeling of LRP12 with either Synapsin I (Figure 4.2.1 A) or PSD95 (Figure 
4.2.1 B) is detected, indicating that it is not specifically enriched in the pre- or 
postsynaptic compartment. 
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Figure 4.2.1: LRP12 is not present at synapses. (A) Co-immunohistochemistry of 
Synapsin I and LRP12 in DIV14 cortical neurons. LRP12 expression is abundant in 
the soma as well as in neurites, but is absent from the nucleus. No co-expression of 
Synapsin I and LRP12 was detectable. LRP12 is not present at the presynapse. (B) 
Co-immunohistochemistry of PSD95 and LRP12. No overlapping expression of 
PSD95 and LRP12 was observed. LRP12 is not present at the postsynapse. Scale 
bar: 50m  
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4.2.2 LRP12 is not localized at the Golgi apparatus  
 
To further investigate the subcellular localization of LRP12, co-
immunohistochemical stainings of LRP12 and GM130, a cis-Golgi matrix protein, 
hence a marker for the Golgi apparatus, were carried out in DIV 14 primary cortical 
neurons. To localize LRP12 within the cell, single-plane confocal pictures as well 
as z-stack images were taken. Whereas single-plane confocal images do not 
clearly unravel, whether LRP12 is present at the Golgi matrix, z-stack images 
indicate that LRP12 is not co-expressed with GM130, thus not located at the cis-
Golgi matrix (Figure 4.2.2). No specific LRP12 localization at the plasma 
membrane is observed.  
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Figure 4.2.2: LRP12 is not localized at the Golgi apparatus. (A) Co-
immunohistochemical stainings of LRP12 and GM130 indicate that both proteins 
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are not co-expressed. The picture represents a single-plane confocal image of DIV 
14 primary cortical neurons. Scale bar: 50m. (B) Co-immunohistochemical 
stainings of LRP12 and GM130. Z-stacks of DIV 14 primary cortical neurons 
demonstrate the absence of LRP12 at the cis-Golgi network. Scale bar: 50m. 
 
 
4.3 Frequent SNP in the LRP12 promoter region of ganglioglioma 
patients 
 
In order to unravel genetic alterations causing reduced LRP12 mRNA transcripts 
in gangliogliomas (Figure 1.4.1) (26), SSCP analysis was carried out as described 
before (27). Ganglioglioma biopsy tissues of patients who underwent surgical 
removal of the tumor as well as blood controls from patients without neurological 
disorders were included in this study. In this context, previously generated SSCP 
and sequencing data were analyzed statistically. 
No mutations or increased allelic variants were observed within the LRP12 coding 
region of ganglioglioma patients as compared to controls. Nevertheless, 
sequencing analysis of the putative LRP12 promoter area revealed a frequent 
SNP within the LRP12 promoter region of ganglioglioma patients. This rs9694676, 
with a base exchange from major T- to minor C-allele is positioned -51 bp 
upstream of the LRP12 transcription start site (Figure 4.3.1). 
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Figure 4.3.1: SSCP and subsequent sequencing analyses reveal a frequent SNP 
located in the potential LRP12 promoter region of ganglioglioma patients. 
 
Intriguingly, the minor C-allele of rs9694676 is significantly increased in 
gangliogliomas (n=20) as compared to individuals without neurological disorders 
(blood controls, n=97; 2-test: p=0.0261 Table 4.3.1) 
 
Table 4.3.1: Allelic frequency of rs9694676 in 20 ganglioglioma patients and 97 
blood controls without neurological disorders. 
 
             group    n  allele T (%) allele C (%)     2        p 
                 GG  20   33 (82.5%)    7 (17.5%)  4.95   0.0261 
controls  97 181 (93.3%)    13 (6.7%)   
 
The relative C-allele frequency is 2.6 times higher in ganglioglioma patients 
compared to controls. Two statistical tests, 2-test and Hardy–Weinberg 
equilibrium (HWE) indicate the genotype frequency of the T- and C-alleles of 
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rs9694676 between gangliogliomas and blood controls to be significantly different 
(2-test: p=0.0326; HWE: p=0.479, Table 4.3.2). 
 
Table 4.3.2: Genotype frequency of rs9694676 in 20 ganglioglioma patients and 97 
blood controls without neurological disorders. 
 
group  n T/T (%) T/C (%) C/C (%) 2 p HWE p 
GG 20 14 (70.0%) 5 (25.0%) 1 (5.0%) 6.85  0.0326   0.479 
controls 97 84 (86.6%) 13 (13.4%) 0 (0.0%)     
 
 
4.4 Biological relevance of rs9694676 
 
4.4.1 Bioinformatic analysis of the putative LRP12 promoter region  
 
Human LRP12 is located on chromosome 8 and consists of 7 exons (38, 43).  
In order to decipher the biological relevance of the T- or C- allelic variants of 
rs9694676 and to address whether this SNP affects the DNA binding affinity of 
transcription factors, a promoter analysis of LRP12 was carried out. Initially, the 
putative human LRP12 promoter region was identified using CpGPlot, COMET 
and Eponine softwares (Figure 4.4.1).  
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Eukaryotic promoters are cis-regulatory elements typically located upstream of a 
gene’s coding sequence. RNA-polymerase-II-dependent promoters may contain 
certain characteristics like TATA boxes, CpG islands and several transcription 
start sites. These frequently occurring motifs offer possibilities to depict potential 
promoter regions in silico (71-73, 83). As promoters may contain some, all or none 
of the above-mentioned characteristics (83), it becomes necessary to apply 
different algorithms with differing search parameters to identify potential promoter 
regions as precisely as possible. By using different software tools, the probability 
of false positive or false negative results is reduced. Here, the potential LRP12 
promoter region was identified on the basis of CpG Islands (CpG plot), TATAAA 
sequences (COMET) and transcription start sites (Eponine). 
 
 
 
Figure 4.4.1: The putative human LRP12 promoter region is characterized by the 
presence of CpG islands. Potential transcription start sites are marked as identified 
by the Eponine software (modified from (84)).  
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Particularly transcription factor binding sites, with matrix similarity scores (MSS) 
significantly altered in the minor C-allele sequence, were screened with 
PoSSuMsearch software. Intriguingly, bioinformatic promoter analysis predicted 
reduced binding affinity of transcription factor STAT5a for the rs9694676 C-allele 
promoter variant. Whereas the major rs9694676 T-allele exhibits a STAT5a 
binding affinity potential of 98.6%, i.e. largely resembling the ideal binding motif for 
this transcription factor, the predicted binding affinity of STAT5a for the minor 
rs9694676 C-allele promoter sequence is only 70.2% (Figure 4.4.2).  
 
 
 
Figure 4.4.2: SNP rs9694676 is positioned 51 bp upstream of the transcription start 
site of the human LRP12 gene. The genomic sequence flanking the SNP contains 
transcription factor binding sites characterized by different matrix similarity scores 
between the T- and C-allele promoter sequences. The transcription factor STAT5a 
shows a binding probability of 98.6% for the major T-allele sequence, whereas its 
binding probability is reduced to 70.2% in the alternative C-allele sequence. 
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4.4.2 Luciferase assays of the LRP12 promoter region  
 
To test these bioinformatic predictions by in vitro analyses, two luciferase reporter 
plasmids under control of a 692 bp LRP12 promoter fragment, containing either 
rs9694676 T- or the C-allele were generated. These plasmids were transfected 
into NG108 cells and promoter activity was analyzed by luciferase assays. 
Rs9694676 T-allele promoter fragment shows a significantly higher basal 
luciferase activity than the alternative C-allele construct (n=4 T-allele, n=3 C-allele; 
ANOVA: p<0.05; Fig. 4.4.3). Exposure of promoter fragments to STAT5a induces 
significant activation of LRP12 rs9694676 T-allele promoter (n=3; ANOVA: p<0.01; 
Fig. 4.4.3), whereas the LRP12 C-allele promoter is not substantially stimulated by 
STAT5a (n=4; ANOVA: p>0.05 Fig. 4.4.3).  
 
 
 
Figure 4.4.3: Luciferase assays of LRP12 rs9694676 C- and T-allele. Basal LRP12 
rs9694676 C-allele promoter activity is significantly lower as compared to T-allele 
activity (ANOVA: p*<0.05). No significant activation of LRP12 rs9694676 C-allele 
promoter by exposure to STAT5a (ANOVA: p>0.05) was observed, whereas the 
LRP12 rs9694676 T-allele promoter was significantly stimulated by STAT5a 
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(ANOVA: p**<0.01). Luciferase activity of the T-allele promoter stimulated with 
STAT5a is strikingly higher than activity of the C-allele fragment co-transfected with 
STAT5a (ANOVA: p***<0.001).  
 
 
4.5 Lack of LRP12 protein in neuronal and astroglial ganglioglioma 
components 
 
Due to the fact that it is virtually impossible to isolate low-grade gangliogliomas 
from preexisting brain under native conditions and gangliogliomas are cellularly 
heterogeneous neoplasms, absolute quantification of LRP12 protein by standard 
methods such as immunoblotting analysis is a major obstacle. In order to, 
nevertheless, provide insight into LRP12 protein expression in neuronal and 
astroglial ganglioglioma components, an obviously semiquantitative method, i.e. 
counting cells in defined areas and stratifying them in three different classes of 
expression intensity was carried out. As suggested by the expression analyses in 
adult rodent brain (Figures 4.1.2 and 4.1.3), the examination of adult human brain 
reveals LRP12 expression to be present in neuronal and astroglial cell 
components (Figures 4.5.1 and 4.5.2). Strikingly, in gangliogliomas there is 
substantially lower expression of LRP12 in the dysmorphic neuronal component 
than in pre-existing brain tissue’s neurons (Figure 4.5.1; n=10 ganglioglioma, n=9 
normal brain tissue; t-test (‘strong’ LRP12 expressing neurons in control brain vs. 
ganglioglioma): p=9.5x10-22; t-test (‘medium’ LRP12 expressing neurons in control 
brain vs. ganglioglioma): p=1.35x10-4; t-test (‘low’ LRP12 expressing neurons in 
control brain vs. ganglioglioma): p=0.0042).  
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Figure 4.5.1: LRP12 protein expression in neuronal ganglioglioma components and 
normal brain tissue. (A) Representative LRP12 and NeuN expression in 
ganglioglioma versus normal brain tissue. Note the more heterogeneous 
orientation and shape of neuronal elements of gangliogliomas in contrast to the 
homogeneous orientation and isomorphic shape of neurons in normal cortical 
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control tissue. Substantially stronger LRP12 expression is present in normal brain 
compared to ganglioglioma. (B) Semiquantitative analysis demonstrates a 
substantially smaller number of NeuN-positive neuronal elements with strong 
expression of LRP12 in gangliogliomas than in controls (n=10 gangliogliomas, n=9 
normal brain tissue; t-test (‘strong’ LRP12 expressing neurons in control brain vs. 
ganglioglioma): p***<0.001; t-test (‘medium’ LRP12 expressing neurons in control 
brain vs. ganglioglioma): p***<0.001; t-test (‘low’ LRP12 expressing neurons in 
control brain vs. ganglioglioma): p**<0.01). Scale bars: 200m. 
 
The general expression of LRP12 in pre-existing neurons appears rather 
homogeneous. In contrast, in pre-existing astroglial cells the expression of LRP12, 
for not resolved reasons, is more heterogeneous. However, there is as well 
substantially less intense expression of LRP12 in gangliogliomas’ glial 
components. Most ganglioglioma astroglial cell elements reveal only low 
expression of LRP12 (Figure 4.5.2; n=13 gangliogliomas, n=8 control brain; t-test 
(‘strong’ LRP12 expressing glial cells in control brains vs. gangliogliomas): 
p=2x10-6; t-test (‘low’ LRP12 expressing glial cells in control brain vs. 
gangliogliomas): p=2x10-5). 
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Figure 4.5.2: LRP12 protein expression in glial ganglioglioma components and 
normal brain tissue. (A) Representative LRP12/GFAP co-expression in a 
ganglioglioma versus non-neoplastic control brain. Astroglial ganglioglioma 
components are smaller and have more delicate processes than the larger reactive 
astroglial cells in adjacent normal brain tissue. Although the expression of LRP12 
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is heterogeneous in preexisting astroglia in normal brain tissue, there are 
numerous cells with strong cytoplasmic expression of LRP12. In contrast, there is 
generally only low expression of LRP12 in the gangliogliomas’ astroglial 
components. (B) The semiquantitative analysis underscores this observation (n=13 
gangliogliomas, n=8 control brain; t-test (‘strong’ LRP12 expressing glial cells in 
control brain vs. ganglioglioma): p***<0.001; t-test (‘low’ LRP12 expressing glial 
cells in control brain vs. ganglioglioma): p***<0.001). Scale bars: A, B: 200m. 
 
 
4.6 Knockdown of LRP12 induces increased proliferation in cultured 
astroglial cells 
 
4.6.1 In vitro testing of shRNA knockdown efficiency in HEK293T cells  
 
Based on reduced LRP12 levels in neoplastic astroglial cells of gangliogliomas 
(Figure 4.5.2) and regarding LRP12’s putative tumor suppressor function 
described in non-brain tumor derived cell lines (38) the question, whether a lack of 
LRP12 alters the kinetics of growing astrocytes was addressed using an shRNA-
mediated knockdown approach. Initially, knockdown efficiency of the respective 
shRNA constructs were tested in HEK293T cells co-transfected with plasmids 
encoding a LRP12_HA fusion protein and different shRNAs (sh749, sh869 and 
sh64) targeted against murine Lrp12 mRNA.  
Generally, posttranscriptional shRNA mediated knockdown leads to reduced 
protein levels in cells. ShRNA constructs are introduced via e.g. transfection, 
transduction or electroporation into the cells of interest. Once the vector has 
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integrated into the host genome, double stranded RNA is expressed and 
subsequently processed by the Dicer enzyme complex into smaller ribonucleotides 
(siRNAs). Afterwards, the so-called ‘RNA-induced silencing complex’ (RISC) is 
formed; thereby double stranded siRNA is cleaved by helicases into single 
stranded RNA. The single stranded RNA-RISC complex associates with its 
complementary mRNA counterpart and mRNA is degraded by RISC’s 
endonuclease activity. As a consequence of reduced mRNA levels, less Protein 
amounts are present in transformed cells (85). 
Here, levels of LRP12_HA are reduced significantly at 72h after transfection by 
individual shRNAs as well as by a combination of equal amounts of the individual 
shRNAs (t-test (U6 vs. sh749): p=0.046; t-test (U6 vs.sh869): p=0.011; t-test (U6 
vs. sh64): p=0.005; t-test (U6 vs. shMix): p=0.030) (Figure 4.6.1 A, B). 
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Figure 4.6.1: In vitro knockdown of LRP12 in HEK293T cells. Analysis of the 
silencing efficiency and specificity of shRNAs targeted against murine Lrp12 
mRNA. HEK293T cells were co-transfected with pCMV-mLRP_HA and different 
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shRNA variants targeted against Lrp12 mRNA (sh749, sh869, sh64, shMix (mixture 
of equal amounts of sh749, sh869 and sh64)). (A) Total cell lysates were prepared, 
and equal lysate fractions were analyzed by immunoblotting. The blots (n=3) were 
probed with antibodies against LRP12 and -Actin as loading control. Numbers on 
the left indicate positions of molecular weight markers. (B) Knockdown efficiency 
was quantified using AIDA software. All shRNA probes resulted in a significant 
reduction of LRP12 protein in HEK293T cells (t-test (U6 vs. sh749): p*<0.05; t-test 
(U6 vs.sh869): p*<0.05; t-test (U6 vs. sh64): P**=0.01; t-test (U6 vs. shMix): p*<0.05). 
 
 
4.6.2 In vitro cell proliferation assays  
 
Subsequently, primary astrocytes were transduced quantitatively with either 
recombinant adeno-associated viral (rAAV) particles encoding the U6-hrGFP 
control plasmid or with a mixture of rAAV particles harboring the tested shRNAs 
(mixture of sh749, sh869 and sh64). LRP12 knockdown in primary astrocytes 
causes an accelerated cell proliferation in vitro. To quantify this effect, in vitro cell 
proliferation assays were carried out. A significantly increased proliferation of 
astrocytes with decreased levels of LRP12 at 4 days (n=10 each; t-test: p=1.0x10-
8), 5 days (n=10 each; t-test: p=2.0x10-5) and 6 days (n=10 each; t-test: p=0.021) 
after transduction with rAAV particles in culture was observed (Figure 4.6.2).  
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Figure 4.6.2: Representative cell proliferation assays of primary astrocytes with and 
without application of Lrp12 mRNA-targeted shRNA mix. The growth kinetics of 
astrocytes with knockdown of LRP12 at days 4, 5 and 6 after transduction with 
Lrp12 mRNA-targeted shMix by rAAV particles is significantly higher than in 
controls (n=10 each; t-test (4 days after transduction): p***<0.001; t-test (5 days 
after transduction): p***<0.001; t-test (6 days after transduction): p*<0.05). As a 
control the U6-hrGFP vector was transduced. 
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4.7 In vitro knockdown of LRP12 leads to substantially impaired 
arborization of developing neurons 
 
4.7.1 In vitro LRP12 knockdown efficiency in neurons  
 
Lrp12 mRNA and LRP12 protein knockdown efficiencies of the respective shRNA 
sequences (sh749, sh869 and sh64) were tested in neurons transduced with rAAV 
particles harboring the respective shRNAs sequence as well as with a mixture of 
all shRNAs. Quantitative RT-PCR and western blot analyses were carried out in 
order to quantify the knockdown effectivity of Lrp12 mRNA and LRP12 protein. 
Levels of Lrp12 mRNA were significantly reduced in DIV14 primary cortical 
neurons transduced with the individual shRNAs at day DIV1 as well as by a 
combination of equal amounts of the individual shRNAs compared to neurons 
transduced with the U6 control plasmid (t-test (U6 vs. sh749): p=0.04; t-test (U6 
vs. sh869): p=0.03; t-test (U6 vs. sh64): p=0.04; t-test (U6 vs. shMix): p=0.002) 
(Figure 4.7.1).  
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Figure 4.7.1: Quantitative RT-PCR of Lrp12 mRNA after treatment with different 
shRNAs. Results indicate significantly less abundant Lrp12 mRNA levels in 
neurons treated with shRNAs against murine Lrp12 mRNA compared to neurons 
transduced with the U6 control plasmid (U6: n=7; sh749: n=8; sh869: n=8; sh64: 
n=8; shMix: n=7; t-test (U6 vs. sh749): p*<0.05; t-test (U6 vs. sh869): p*<0.05; t-test 
(U6 vs. sh64): p*<0.05; t-test (U6 vs. shMix): p**<0.01). 
 
For subsequent western blot analysis primary cortical neurons were transduced 
with rAAV particles encoding the respective shRNA sequences of sh749, sh869 
and sh64 as well as with a mixture of all shRNAs on DIV1. Western blot analysis 
reveals strongly reduced levels of LRP12 protein in DIV14 primary cortical neurons 
(Figure 4.7.2).  
 
Results 
 81 
 
 
Figure 4.7.2: Western blot analysis of LRP12 protein levels after shRNA-mediated 
knockdown with shRNAs against murine Lrp12 mRNA. Treatment with shRNAs 
sh749, sh869, sh64 and with a mixture of all three shRNAs results in reduced LRP12 
levels.  
 
 
4.7.2 In vitro arborization analyses 
 
Considering the unique cytological aspects of gangliogliomas, i.e. dysplastic and 
immature neuronal cell components, it was examined whether reduced LRP12 
levels may impair neuronal development. By using a parallel approach as 
described above, primary cortical neurons were transduced with rAAVs encoding 
either LRP12 targeted shRNAs or the control plasmid U6-hrGFP. Whereas primary 
cortical neurons transduced with the U6-hrGFP control plasmid reveal an 
unaltered, delicately arborized pattern of processes, neurons with reduced 
expression of LRP12 exhibit a substantial structural impairment. Altered 
arborization of these neurons is present at proximal as well as distal ends of 
processes. Quantitatively, increased branching of proximal neurites in neurons 
lacking LRP12 was observed (Figure 4.7.3) (n=5 each; t-test (50m analysis 
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diameter): p=1,0x10-4; t-test (75m analysis diameter): p=2.0x10-3) resembling the 
findings in neuronal components of gangliogliomas (Figure 1.3.1 D). In contrast, 
arborization of dendrites is significantly reduced in distal parts of Lrp12 mRNA-
shRNA exposed neurons compared to controls (Figure 4.7.3) (n=5 each; t-test 
(275m analysis diameter): p=4.0x10-3). 
 
 
 
Figure 4.7.3: In vitro knockdown of LRP12 in primary neurons. (A) Representative 
images of primary cortical neurons at DIV14 transduced with either the control 
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vector U6-hrGFP or the LRP12 directed shRNA U6-sh869 vector via rAAV particles 
serotype 1/2 at ‘day 1 in vitro’ (DIV1). Substantial morphological impairment of 
dendritic arborization is present in cortical neurons transduced with U6-sh869. 
Scale bar: 50m. (B) Lack of LRP12 induces an aberrant neuronal phenotype, i.e. 
increased dendritic branching of developing cortical neurons at the proximal (n=5 
each; t-test (50m diameter of analysis): p***<0.001, t-test (75m diameter of 
analysis): p**<0.01) as well as a reduced density of neurites at the more distal 
processes of shRNA treated neurons (n=5 each; t-test (275m diameter of analysis): 
p*<0.5). Photographed cells were analyzed morphometrically with Fiji. 
 
 
4.8 Embryonic knockdown of LRP12 by intraventricular in utero 
electroporation in mice leads to impaired migration of neurons 
 
4.8.1 In vivo knockdown efficiency of LRP12 
 
In vivo knockdown efficiency of LRP12 in neurons was tested via co-
immunohistochemical stainings. Therefore, an antibody against LRP12 (Biobryt) 
and a monoclonal hrGFP antibody were applied. Vibratome slices were stained 
with antibodies; afterwards maximum intensity projections of confocal z-stack 
images were taken in brain areas of electroporated neurons adjacent to non-
electroporated cells. The cell fluorescence, serving as a measurement for LRP2 
protein levels, was quantified using Fiji. Neurons electroporated with shRNAs 
against murine Lrp12 mRNA exhibit significantly less fluorescence compared to 
nearby non-electroporated cells indicating, that treatment with shRNAs leads to 
significantly less amounts of LRP12 protein in vivo (Figure 4.8.1) (non-
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electroporated neurons: n=45; electroporated neurons: n=26; t-test (no-
electroporated neurons vs. electroporated neurons): p=2.5x10-6). 
 
 
 
Figure 4.8.1: Quantification of LRP12 in vivo knockdown efficiency in neurons. 
Embryonic mice were electroporated on day E16 with shRNAs (shMix) against 
murine Lrp12 mRNA. Mice were sacrificed on day P21. Vibratome slices were co-
immunohistochemically stained with antibodies against LRP12 and hrGFP. (A) 
Representative image of an electroporated neuron in the proximity of non-
electroporated neurons. Treatment with shRNAs results in less intense LRP12 
fluorescence, indicating lower LRP12 amounts in these cells. (B) Quantification of 
cell fluorescence was carried out using Fiji. Total LRP12 cell fluorescence was 
calculated using the following formula: total cell fluorescence = integrated density 
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– (area of selected cell x mean fluorescence of background readings). 
Electroporation of shRNAs against Lrp12 mRNA leads to significantly reduced total 
LRP12 cell fluorescence levels in electroporated neurons, giving evidence to 
significantly reduced LRP12 protein levels (non-electroporated neurons: n=45; 
electroporated neurons: n=26; t-test (no-electroporated neurons vs. electroporated 
neurons): p***<0.001).  
 
 
4.8.2 Embryonic knockdown of LRP12 leads to impaired migration of 
neurons 
 
To address whether reduced expression levels of LRP12 lead to impaired 
migration and/or differentiation of developing neurons in vivo, i.e. resembling 
dysmorphic and/or aberrantly clustered neuronal components of gangliogliomas 
(Figure 1.3.1), intraventricular in utero electroporation (86, 87) was used. For 
knockdown of LRP12 in developing mice, shRNAs against murine Lrp12 mRNA as 
well as the U6-hrGFP control plasmid and a plasmid containing RFP, were 
electroporated at day E16. To analyze control and test animals from within the 
same litter, the U6-hrGFP control vector was co-electroporated with the RFP 
containing plasmid as a marker to distinguish between control and shRNA treated 
animals (Figure 4.8.2 C). This particular time point was chosen in order to hit 
neuronal precursor cells with active migration and differentiation. To determine 
whether reduced expression of LRP12 impairs normal migration of neocortical 
neurons, positions of neurons lacking LRP12 and control neurons were examined 
after murine cortex maturation, i.e. at day P21. Intriguingly, significantly aberrant 
cortical architecture is present in with shRNA-electroporated mice (Figure 4.8.2 A). 
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Whereas in control animals, electroporated neurons migrate throughout the 
external granular layer, neurons with decreased levels of LRP12 mostly remain at 
the border between the external granular layer and the external pyramidal layer 
(Figure 4.8.2 B) (n=5 controls, n=7 LRP12 knockdown animals; ANOVA (upper 
external granular layer LRP12 knockdown animals vs. lower external granular 
layer LRP12 knockdown animals): p<0.001; ANOVA (upper external granular layer 
LRP12 knockdown animals vs. upper external granular layer control animals): 
p<0.05; ANOVA (lower external granular layer LRP12 knockdown animals vs. 
lower external granular layer control animals): p<0.05).  
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Figure 4.8.2: Aberrant positioning of neurons in cortical laminae after 
intraventricular in utero knockdown of LRP12. (A) Representative areas of aberrant 
cortical development in Lrp12 mRNA-shRNA in utero electroporation-treated 
animals. As control, the U6-hrGFP vector in combination with an expression 
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plasmid for red fluorescent protein (RFP) was co-electroporated. Cortical layers of 
electroporated mice were characterized by DAPi and NeuN stainings. Whereas in 
control animals, electroporated neurons migrate throughout the external granular 
layer (egl), neurons lacking LRP12 show frequent aberrant positions pointing 
towards impaired migration. They are mostly found at the border between the 
external granular layer and the external pyramidal layer (epl). Molecular layer (ml), 
internal granular layer (igl). Scale bar: 1000m. (B) Quantitative analysis of aberrant 
migration in mice after intraventricular in utero knockdown of LRP12 based on 
DAPi and NeuN immunohistochemistry. The granular cell layer was further 
subdivided into upper external granular layer (uegl) and lower external granular 
layer (legl). Quantification was carried out using Fiji software. (n=5 controls, n=7 
LRP12 knockdown animals; ANOVA (upper granular layer LRP12 knockdown 
animals vs. lower granular layer LRP12 knockdown animals): p***<0.001; ANOVA 
(upper granular layer LRP12 knockdown animals vs. upper granular layer control 
animals): p*<0.05; ANOVA (lower granular layer LRP12 knockdown animals vs. 
lower granular layer control animals): p*<0.05). (C) Plasmids used for IUE. 
 
In addition to the impaired migration behavior of neurons lacking LRP12, an 
aberrant neuronal positioning within the cortical structure was observable in some 
of the animals electroporated with shRNAs (Figure 4.8.3). Reduced LRP12 levels 
lead to aberrant migration and cortical positioning of developing neurons. 
However, no lesions with a neuroglial composition immediately resembling 
gangliogliomas are present after shRNA in utero electroporation in mice. 
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Figure 4.8.3: Aberrant positioning and irregular orientation of neurons lacking 
LRP12 within the cortical architecture. Mice were electroporated at day E16 with 
shRNAs against murine Lrp12 mRNA and sacrificed at day P21. Scale bars: A, B: 
200m; C, D: 100 m. 
 
 
4.8.3 Positioning of electroporated neurons within cortical laminae 
 
In order to depict the cortical layers electroporated neurons migrate to, co-
immunohistochemical stainings of CUX1 and hrGFP were carried out. CUX1 is 
expressed in the external granular layer (cortical layer II), the external pyramidal 
layer (cortical layer III) and the external pyramidal layer (layer IV) and is therefore 
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used as a marker for the upper cortical layers (88). Since specific antibodies for 
distinct cortical layers are not available on the market, CUX1 was used to 
differentiate whether electroporated cells migrate to the upper or lower cortical 
layers. Co-immunohistochemical stainings against CUX1 and hrGFP reveal, that 
both control neurons as well as neurons with decreased LRP12 levels are 
localized in the upper cortical layer II, III and IV at day P21 (Figure 4.8.4). 
 
 
 
Figure 4.8.4: Positioning of electroporated neurons within cortical laminae. 
Vibratome slices of electroporated mice were co-immunohistochemical stained with 
antibodies against CUX1 and hrGFP. Electroporated neurons of control and test 
animals were found to migrate throughout the upper cortical layers. Scale bar: 
500m. 
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4.9 Increased propensity to PTZ-induced seizures in mice after LRP12 
shRNA in utero electroporation 
 
Subsequently, the question was addressed whether the observed 
neuropathological alterations after LRP12 in utero electroporation knockdown in 
mice correlate with increased seizure susceptibility. To address this issue, mice 
were electroporated at day E16 as describes above. At day P40 these mice were 
subjected to PTZ experiments. Thereby, 10mg/kg PTZ was injected 
intraperitoneally every 10 minutes until the occurrence of the first seizure event 
(Figure 4.9 B). For evaluation seizures were grouped into focal and generalized 
seizures. Intriguingly, the severity of seizures induced by PTZ in LRP12 
knockdown animals was significantly higher. Whereas control animals 
preferentially exhibit focal seizures as first epileptic manifestation, LRP12 
knockdown animals have more serious, generalized seizures as their first epileptic 
event (n=6 controls, n=11 LRP12 knockdown animals; Fisher’s exact test: 
p=0.028) (Figure 4.9 A). The time point of seizure onset after PTZ injection or the 
PTZ-dosages to elicit seizures between LRP12 knockdown animals and control 
mice does not differ (n=6 controls, n=11 LRP12 knockdown animals; t-test (time 
point of first epileptic seizure): p=0.67; t-test (PTZ-dosage): p=0.77).  
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Figure 4.9: Increased PTZ-induced seizure severity in mice after in utero 
electroporation with Lrp12 mRNA targeted shRNAs. (A) Comparison of the severity 
of the first occurring seizures in LRP12 knockdown animals and control animals. A 
significantly higher number of generalized seizures among LRP12 knockdown 
animals was observed (n=6 controls, n=11 LRP12 knockdown animals; Fisher’s 
exact test: p*<0.05). No differences of the first time occurrence of an epileptic event 
and PTZ-dosages to elicit seizures were detected between control and LRP12 
knockdown animals (t-test (time of first occurring seizure): p>0.05; t-test (PTZ 
dosage of first occurring seizure): p>0.05). (B) Work flow of the analysis of PTZ-
induced seizure sensitivity in in utero electroporated mice. In order to determine 
seizure sensitivity, 10mg/kg of PTZ were injected every 10 minutes until the first 
onset of epileptic seizures. 
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5. Discussion 
 
Gangliogliomas are the most frequent tumor entity found in temporal lobe 
resection specimens of patients suffering from focal, pharmacoresistant epileptic 
seizures (13, 17). These multifactorial malformations are thought to originate from 
developmentally comprised precursor cells. Histopathologically they reveal a 
biphasic architecture, composed of dysplastic neurons as well as highly 
differentiated and proliferative glial cells (18, 20). Nevertheless, the molecular 
pathomechanisms leading to the manifestation of gangliogliomas are only poorly 
understood (26). 
The hypothesis of LRP12 being a crucial factor for the pathogenesis and 
manifestation of gangliogliomas is based on expression array data by Fassunke et 
al. (2008), which unraveled less abundant LRP12 mRNA transcripts in 
gangliogliomas as compared to control tissue. This assumption is underlined by 
the striking characteristics of LRP12 as a tumor suppressor molecule, its abundant 
expression during cortex formation as well as by the key regulator function for 
neuronal migration of its homologue MIG-13 in C. elegans (26, 37, 38, 52, 53). 
In summary, the aim of this study was to investigate LRP12’s contribution to the 
pathogenesis and manifestation of gangliogliomas. Thereby, the focus was on 
genetic and expression modifications of LRP12 in gangliogliomas as well as on in 
vitro and in vivo LRP12 knockdown studies. We addressed the question whether 
reduced levels of LRP12 influence astroglial proliferation, neuronal arborization 
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and migration in the context of ganglioglioma pathogenesis. Additionally, a 
detailed characterization of LRP12, including expression patterns in embryonic 
and adult mouse brain, posttranscriptional modifications and the subcellular 
localization, was carried out. 
Lrp12 is a homologue of mig-13. This gene is critically involved in the accurate Q 
neuroblast migration and positioning along the anteroposterior axis in C. elegans. 
Therefore, MIG-13 is present in migrating neurons. Additionally, it acts non-cell 
autonomously on migration processes (52, 53). Furthermore, Lrp12 has been 
reported as highly expressed in preplate neurons during cortical plate formation in 
mice (37). Nevertheless, LRP12 expression patterns in embryonic and adult 
mouse brains have not been analyzed thoroughly. 
For verification of antibody specificity immunoblotting analyses of native HEK cells 
and HEK cells overexpressing murine LRP12_HA was carried out. Labeling with 
antibodies against LRP12 and the HA-tag respectively, demonstrate a specific 
LRP12 band at 110kDa in cells overexpressing LRP12_HA. The band at 92kDA, 
also present in non-transfected HEK cells, originates from an unspecific cross-
reaction of the LRP12 antibody with an unknown epitope (Figure 4.1.1). Sequence 
alignment of the antibody’s immunogen sequence with homologous proteins 
reveals 45% sequence identity with human LRP3, a protein closely related to 
LRP12 (43, 89). It remains to be tested, whether the unspecific band at 92kDA is 
caused by interaction of the antibody with LRP3. 
Characterization of LRP12 expression during embryogenesis (E13.5) and in adult 
mice together with an analysis of spatial LRP12 expression differences in adult 
mouse brain was carried out. The protein is present in embryonic and adult whole 
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brain lysates. A specific LRP12 band is detectable at 110kDA (Figure 4.1.2), 
indicating that LRP12 is critical during embryogenesis as well as in adult mice.  
Western blot analysis of brain areas of adult mice, e.g. spinal cord, medulla, 
cerebellum, thalamus, hippocampus, striatum, temporal cortex, frontal cortex and 
olfactory bulb was carried out. Diverse levels of LRP12 are present in different 
brain areas. Generally, LRP12 expression is high in medulla, olfactory bulb, 
temporal and frontal cortex, with being most abundant in medulla and olfactory 
bulb (Figure 4.1.3). In situ hybridization data from the Allen Brain Atlas 
demonstrate low Lrp12 mRNA levels in adult mice. Highest mRNA amounts are 
present in the olfactory bulb, hippocampus, cortex and medulla (90). Regarding 
medulla, olfactory bulb and cortical brain regions, Lrp12 mRNA levels correlate 
well with LRP12 protein amounts. Differences between mRNA expression and 
protein abundance, for example in the hippocampal formation, suggest Lrp12 
expression to be regulated at both the transcriptional and posttranscriptional level. 
Data by Qing et al. showing discrepancies between mRNA and protein expression 
in several malignant cell lines support this assumption (38). Mechanisms of 
posttranscriptional Lrp12 mRNA regulation remain to be investigated. High levels 
of LRP12 in medulla and olfactory bulb could inhibit the formation of 
gangliogliomas in these brain areas. Literature supports this idea, as only 3% of 
gangliogliomas are located in the brain stem (91). However, no data about 
gangliogliomas located in the olfactory bulb are published. Gangliogliomas are 
commonly localized within the temporal cortex; in this brain area LRP12 
expression is high in non-neoplastic cells (Figure 4.1.3, 4.5.1 and 4.5.2). In 
contrast, ganglioglioma specimens demonstrate reduced LRP12 levels in 
tumorous tissue (Figure 4.5.1 and 4.5.2). These correlations suggest, that lowered 
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LRP12 amounts in temporal cortical areas foster the formation of epilepsy-
associated gangliogliomas. Considering the varying LRP12 amounts in distinct 
brain areas, the preferential neocortical localization of gangliogliomas as well as 
less LRP12 amounts in neocortical ganglioglioma tissue, it may hypothesized, that 
an equilibrium of LRP12 in particular brain regions, e.g. temporal cortex influences 
the susceptibility for the formation of gangliogliomas.  
We found LRP12 to be subject to posttranslational modification by N-glycosylation 
(Figure 4.1.4). N-glycosylation may affect the folding, oligomerization or stability of 
proteins (92, 93). For LRP12 homologues such as LRP6, glycosylation of the 
protein has substantial effects on pathways critical for growth and maturation (82). 
Also for LRP12, a role in endocytotic processes and the modification of 
intracellular signal transduction were proposed (43). The dynamic modulation of 
LRP12 may be involved in regulating the function of the molecule in neuronal 
development and astroglial growth. 
LRP12 is a low-density lipoprotein receptor-related protein, closely resembling 
other members of this superfamily, e.g. LRP3 and murine LRP9. Analysis of 
LRP12’s amino acid structure suggests LRP12 to be a transmembrane protein. 
Structural comparison of LRP12, LRP3 and murine LRP9 points to a novel LDLR-
subfamily consisting of these 3 proteins. Common features of this subfamily 
comprise homologous extracellular domains, a single-pass transmembrane 
domain as well as a cytoplasmic tail, which is supposed to interact with other 
molecules putatively involved in endocytosis or signal transduction processes (43). 
Despite its potential transmembrane characteristics, LRP12’s subcellular 
localization has not been investigated thoroughly. Immunohistochemistry of 
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primary cortical neurons with an antibody against LRP12 demonstrates its 
presence in the soma as well as in neurites. Furthermore, LRP12 is absent from 
the nucleus. Even though the resolution of confocal microscopy does not allow for 
an unequivocal identification of a pre-or postsynaptic localization of LRP12, double 
immunolabelings of primary cortical neurons against LRP12/Synapsin I and 
LRP12/PSD95, suggest LRP12 to be not localized at the pre- or postsynapse 
(Figure 4.2.1). Further, co-stainings of LRP12/GM130 demonstrate no LRP12 
expression at the cis-Golgi matrix (Figure 4.2.2). Taken together, these findings 
suggest that LRP12 is not directly involved in pre- or postsynaptic activities as well 
as in reactions taking place at the Golgi apparatus or formation and maintaining 
processes of the Golgi network. Regarding, LRP12’s putative transmembrane 
characteristics (38, 43), neither from single-plane confocal images (Figure 4.2.1 
and 4.2.2), nor from z-stacks of primary cortical neurons (Figure 4.2.2) an 
exclusive LRP12 expression at the plasma membrane was detectable. Further co-
immunohistochemical analyses with antibodies against other subcellular 
compartments will have to be carried out in order to determine LRP12’s subcellular 
localization. 
Somatic mutations represent major alterations of genes involved in brain tumor 
pathogenesis (40, 41). Mutations in gangliogliomas have been described either in 
almost anecdotic frequencies for individual genes (27, 94, 95) or they show 
overlap with mutations reported frequently in other low-grade neuroepithelial 
tumors including pilocytic and diffuse astrocytomas (31, 33). But, key molecular 
pathomechanisms specifically promoting the development of gangliogliomas still 
have to be uncovered.  
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To identify molecular mechanisms causing reduced LRP12 mRNA expression in 
ganglioglioma tissue (26), accompanied with lower LRP12 protein amounts in 
tumor affected neurons and astrocytes (Figure 4.5.1 and 4.5.2), SSCP and 
sequencing analyses of the LRP12 coding and promoter region were carried out. 
These analyses uncovered, that no coding mutation of LRP12 but an allelic 
promoter variant is highly accumulated in ganglioglioma tissue (Figure 4.3.1). Our 
data suggest this variant to influence LRP12 promoter activity. 2-test and Hardy–
Weinberg equilibrium (Table 4.3.1 and 4.3.2) demonstrate, minor rs9694676 C-
allele to be significantly increased in ganglioglioma samples as compared to blood 
controls without neurological disorder. 
Based on these findings, one aim of this study was to answer the question, 
whether the rs9694676 C-allele is of critical functional relevance for LRP12 
promoter activity in vitro. To address this issue, bioinformatic analyses of the 
putative human LRP12 promoter region and potential transcription factor binding 
sites were performed. For bioinformatic analyses a number of computational tools 
are available, all of them applying different search parameters. Here, we chose 
three software tools, e.g. CpGPlot, COMET and Eponine TSS finder, enabling us 
to delineate the putative human LRP12 promoter region on the basis of CpG 
islands (CpGPlot), TATAAA consensus sequences (COMET) and transcription 
start sites (Eponine) (Figure 4.4.1). It has to be noted, that the algorithm for 
detection of transcription start sites via Eponine is based on the identification of 
TATAAA motifs and CG-enriched sequences. In combination with CpGPlot and 
COMET, this leads to redundancy and reproducibility of our promoter analysis, 
ensuring higher reliability of in silico promoter analyses.  
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Subsequently, screening of transcription factor binding sites uncovered 
significantly reduced matrices similarity scores (MSS) for STAT5a in the minor C-
allele sequence as compared to the MSS for the major T-allele (Figure 4.4.2). 
Thereby, high matrix similarity scores reflect high binding probabilities of 
transcription factors and vice versa. To disclose, whether rs9694676 C-allele 
exerts an effect on LRP12 promoter activity in vitro, Luciferase assays were 
carried out. These assays demonstrated the rs9694676 C-allelic LRP12 promoter 
to be significantly less active than its T-allele counterpart. Furthermore, the 
transcription factor STAT5a, which is strongly expressed particularly in developing 
forebrain (96) substantially loses the ability to activate the LRP12 promoter 
rs9694676 C-allelic variant (Figure 4.4.3). We believe there is evidence for the 
rs9694676 C-allele to influence LRP12’s expression in gangliogliomas. On the one 
hand, the rs9694676 C-allele, which is significantly increased in ganglioglioma 
specimens, deceases LRP12 promoter activity in vitro. On the other hand, 
expression array analysis uncovered low LRP12 mRNA levels in gangliogliomas 
(26) and semiquantification of LRP12 revealed reduced protein levels in 
dysmorphic neurons and neoplastic astrocytes (Figure 4.5.1 and 4.5.2). Therefore, 
we propose, that the rs9694676 C-allele may have a role for reduced LRP12 
protein levels in both ganglioglioma cell compartments. Additionally, expression 
array analysis demonstrates low STAT5a mRNA expression in gangliogliomas 
(26). Possibly, the rs9694676 C-allele and low STAT5a mRNA abundance in 
gangliogliomas act synergistically causing low LRP12 levels in gangliogliomas. To 
date, limited data are available regarding correlations of genetic expression 
alterations due to specific promoter variants and their relationship to brain tumors. 
Nevertheless, one of the few studies dealing with this issue demonstrated a 
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PDGFRA promoter polymorphism to be associated with primitive neuroectodermal 
tumors (97). In contrast to mutations, SNPs occur with higher frequencies in the 
population. SNPs are highly abundant single nucleotide base exchanges, 
associated with for example diversity in population, individual response to 
medicine or disease susceptibility (98). Gangliogliomas are caused by alterations 
of numerous genes as well as possibly environmental parameters. Consequently, 
single nucleotide polymorphisms within promoter regions may constitute a new 
regulatory mechanism modifying gene expression in the context of ganglioglioma 
pathogenesis. It needs to be noted, that the rs9694676 C-allele is significantly 
increased in ganglioglioma patients (17.5%), but also present in blood controls 
without neurological disorders (6.7%). Thus, the rs9694676 C-allele may be an 
important factor or modifying parameter for reduced LRP12 mRNA and LRP12 
protein levels in gangliogliomas, adding up to factors in a multifactorial disorder. 
Considering LRP12’s putative suppressor function in solid tumors such as 
fibrosarcomas (38) as well as the proliferative astroglial component of 
gangliogliomas (20), one aim of this study was to find out, whether a lack of 
LRP12 is sufficient to increase astroglial proliferation in cell culture, reflecting a 
key feature of glial cells of these neoplasms. To address this issue, an shRNA-
mediated knockdown approach was applied. LRP12 knockdown efficiency was 
confirmed via Western blot analysis in HEK cells (Figure 4.6.1). Cell proliferation 
assays showed, that reduced LRP12 levels elicit increased growth kinetics in 
primary murine astrocytes (Figure 4.6.2). Remarkably, publications implicate a 
tumor-related function of LRP12 for tumorigenesis. Qing et al. depict LRP12 as a 
tumor suppressor molecule as mRNA and protein levels are low or undetectable in 
several tumor-derived cell lines. In contrast, high-resolution array comparative 
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genomic hybridization results by Garnis et al. suggest LRP12 to act as an 
oncogene in head and neck epithelial carcinogenesis (38, 99). These contradictory 
findings give rise to questions concerning LRP12’s role in the context of neoplastic 
transformation of astroglial cells in gangliogliomas. In our opinion, our in vitro cell 
proliferation results as well as reduced LRP12 amounts in neoplastic astrocytes of 
gangliogliomas (Figure 4.5.2) underline, at least in in the context of 
gangliogliomas, the putative tumor suppressor function of LRP12 described 
before. Given the sporadic emergence and putatively multigenetic character of 
gangliogliomas, the rs9694676 C-allele in gangliogliomas appears as rather 
frequent genetic factor with the potential of promoting tumorigenesis by astroglial 
growth acceleration. It should be emphasized, that this data do not argue against a 
general ‘two hit’ concept to be valid for gangliogliomas (20). Reduced levels of 
LRP12 certainly do not represent the ‘neoplastic hit’ of gangliogliomas, but act in 
concert with a neoplastic transformation, e.g. by alterations of BRAF (31). Less 
abundant LRP12 amounts may promote astroglial proliferation in gangliogliomas, 
for instance where the astroglial component of a dysplastic, developmentally 
compromised precursor lesion is neoplastically transformed by an acquired 
genomic alteration (27, 31).  
Keeping LRP12’s reported neurodevelopmental impact (37, 52, 53) and the 
dysplastic neuronal phenotype of gangliogliomas (20) in mind, a goal of this study 
was to evaluate whether a lack of LRP12 is sufficient to impair neuronal 
development. For gangliogliomas, a pathognomonic feature is given by irregularly 
located, sometimes dysmorphic neurons, which argues for a pathogenetic process 
with primary manifestation during early embryogenesis. In this context, shRNA 
mediated LRP12 in vitro knockdown studies were carried out. LRP12 knockdown 
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efficiency in primary cortical neurons was confirmed by qRT-PCR- and Western 
blot analyses, which both demonstrate significantly less Lrp12 mRNA, respectively 
LRP12 protein levels in neurons (Figure 4.7.1 and 4.7.2). In vitro experiments with 
Lrp12 mRNA-targeted shRNAs in primary neuronal cell cultures showed 
substantial aberrant arborization of neurons with decreased levels of the protein. 
These neuronal cells exhibit increased ramification of proximal processes (Figure 
4.7.3), which reflects findings in the neuronal components of gangliogliomas 
(Figure 1.3.1). It could be hypothesized, that neuronal circuits comprising 
functional elements with such altered morphology possess aberrant connectivity 
and impaired signaling. This again might result in hyperexcitability of affected 
tissue accompanied with lowered threshold for epileptic seizures. This scenario 
could as well account for epilepsy-associated gangliogliomas.  
Regarding the putative neurodevelopmental origin of gangliogliomas, the 
morphological hallmarks of their neuronal elements, including the loss of 
cytoarchitectural organization, clustered appearance and aberrant localization (20, 
70), the abundant expression of LRP12 during murine corticogenesis (37) as well 
as the abnormal morphological appearance of neurons lacking LRP12 (Figure 
4.7.3), the question came up, whether decreased levels of LRP12 lead to aberrant 
neuronal migration during cortical development. This issue was addressed using 
an in utero electroporation knockdown approach. Today, several approaches for 
manipulating gene expression in vivo are available. Generation of transgenic 
animals, viral injection and in utero electroporation are commonly used tools, 
which all have certain advantages and disadvantages. The development of 
knockout mice is laborious, time-consuming and expensive. Viral injection offers 
an effective alternative with very high transduction efficiencies of cells. However, 
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viral infection also has its shortcomings as it may induce immune responses, 
potentially hampering the interpretation of the experimental outcome. In contrast to 
that, in utero electroporation offers a fast and simple approach for influencing 
target gene expression in developing mouse brains (100, 101). In particular with 
respect to disclosing molecular pathomechanisms fostering the manifestation of 
epilepsy-associated gangliogliomas, in utero electroporation offers many 
advantages enabling the experimenter to describe the pathogenesis of these 
neoplasms in animals. In this context, the in utero electroporation animal model 
benefits from high transfection rates in relatively smalls brain areas, reflecting the 
focal lesional character of gangliogliomas (20, 70, 100, 101). Additionally, by 
electroporating shRNA constructs targeting the mRNA of the gene of interest, 
protein expression is not suppressed completely, like e.g. in knockout animals, but 
down-regulated (85). This experimental set-up mirrors the alteration of LRP12 
expression in gangliogliomas authentically, as levels of LRP12 are significantly 
lower in tumorous than control cells, but not completely vanished. Not least, in 
utero electroporation enables the researcher to control transfection spatially and 
temporally. Thereby, the transfection site along the ventricular zone can be 
directed by the orientation of the electric field of the given pulse. As this method 
enables the researcher to selectively target cell populations in the cerebral cortex 
in accordance to the point in time of electroporation during embryogenesis, we 
choose to carry out our electroporations at day E16 in order to hit neuronal 
precursor cells with active migration and differentiation (102, 103). Initially, in vivo 
knockdown of LRP12 was confirmed (Figure 4.8.1). Intriguingly, analysis of 
electroporated animals revealed migration deficits of neurons in animals lacking 
LRP12. These results are in line with LRRP12’s, respectively MIG-13’s, role for 
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neuronal migration in mice and C. elegans (37, 52, 53). Schneider et al. reported 
on LRP12’s highly abundant expression in preplate neurons designated for the 
developing subplate. Using a siRNA electroporation approach in murine 
neocortical, coronal slices of day E11.5, they found that silencing LRP12 inhibits 
cell migration in LRP12-expressing cells, as well as the migration of other cells in 
the developing cortex (37). In addition to that, Sym et al. and Wang et al. 
discovered MIG-13’s essential function for accurate cell migration along the 
anteroposterior body axis in C. elegans, whereat the loss of MIG-13 leads to 
inaccurate cell positioning. Both authors discuss MIG-13’s influence on cell 
migration controversially. Whereas Sym et al. propose a non-cell autonomous 
impact on migrating cells, Wang et al. suggest that mig-13 is a target of Hox 
proteins, cell autonomously regulating Q neuroblast migration processes. Thereby, 
MIG-13 functions as a control molecule for the asymmetric distribution of actin 
cytoskeleton in the leading migratory edge (52, 53). Our results underline the 
assumption of a cell autonomous role in cell migration, as cortical neurons lacking 
LRP12 fail to migrate correctly. Naturally, our data do not exclude an additional 
non-cell autonomously function of LRP12 for cellular migration processes. Taken 
together, these results indicate a crucial role of LRP12 for well-regulated neuronal 
migration and cell positioning during murine corticogenesis.  
Consequences of decreased LRP12 levels were not only addressed regarding 
aberrant neuronal migration and positioning during cortical development, but also 
concerning an increased propensity for epileptic seizures. To answer this issue 
PTZ-induced seizure studies were carried out. In this context, in utero 
electroporated mice were exposed to PTZ until the occurrence of the first epileptic 
event (Figure 4.9). PTZ experiments demonstrate, that animals lacking LRP12 
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exhibit an increased propensity for generalized seizures compared to control 
animals (Figure 4.9). In this context, it needs to be noted, that although neurons 
lacking LRP12 fail to migrate correctly within cortical laminae (Figure 4.8.2), no 
clearly epileptogenic tumorous tissues, e.g. gangliogliomas, were observed in 
electroporated brain areas. Whether enhanced seizure susceptibility is evoked by 
aberrantly assembled neuronal networks or by reorganization of protein 
homeostasis facilitated by reduced LRP12 levels remains to be uncovered. It is 
nonetheless possible, that both aspects foster seizure susceptibility in neuronal 
networks with decreased LRP12. 
Based on the results of this study, the following scenario leading to the 
development of gangliogliomas may be derived: 
The presence of the rs9694676 C-allelic variant causes a deficit of LRP12 protein, 
which is essential during brain development. By passing a virtual pathological 
threshold, this lack of LRP12 manifests as ‘cortical malformation’ that serves as 
precursor lesion of gangliogliomas. However, such dysmorphic precursor lesions, 
though reducing the threshold for epilepsy, presumably are not themselves 
sufficient as epileptogenic. Growth of the astroglial ganglioglioma component 
based on neoplastic transformation (27, 31) apparently is important for 
epileptogenicity due to potential mechanisms including disruption of the anatomic 
architecture and conduction routes of the brain, cortical deafferentiation, 
immediate physical effects such as stretching of CNS tissue, impaired 
neurotransmitter and/or ion homeostasis and interplay between tumor and 
surrounding tissue (104-108). The present data is in line with the rs9694676 C-
allele and LRP12 as potential factors to establish an initial malformative neuronal 
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precursor lesion of multifactorial gangliogliomas and foster aberrant astroglial 
proliferation. The analysis of relevant genomic factors in the risk assessment for 
multifactorial disorders such as epileptogenic brain tumors in diagnostic and 
therapeutic dimensions remain objectives for the future. 
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6. Summary 
 
Gangliogliomas represent chronic epilepsy associated low-grade brain tumors, 
composed of dysmorphic neurons as well as proliferative glial cells. To date, the 
molecular pathomechanisms leading to the manifestation of these multifactorial 
neoplasms are still unknown. The differentiated glial phenotype, the focal nature, 
the benign clinical prognosis together with the expression of the stem cell marker 
CD34 underline the idea of a maldevelopmental origin (18, 20, 26). LRP12 (Low-
density lipoprotein receptor-related protein 12) is critical for brain development and 
involved in tumorigenesis of non-cerebral neoplasms (37, 38). This study 
investigated LRP12’s contribution for the pathogenesis of gangliogliomas by using 
multiple complementary approaches including LRP12 in vitro and in vivo 
knockdown studies. Lower LRP12 mRNA expression in gangliogliomas (26), 
associated with a specific LRP12 promoter variant was observed. Rs9694676 C-
allele, frequent in ganglioglioma patients leads to a significantly lower basal LRP12 
promoter activity in vitro and inhibits activation by the transcription factor STAT5a. 
LRP12 protein expression is strong in embryonic/adult mouse brains but reduced 
in neuronal and astroglial ganglioglioma cells. In vitro knockdown of LRP12 in 
primary neurons and astroglia results in impaired neuronal arborization and 
increased glial growth kinetics, respectively. In vivo knockdown of LRP12 by 
intraventricularly in utero electroporated shRNAs elicits aberrant cortical 
architecture and increased PTZ-induced seizure severity. Accumulation of 
functional promoter-associated allelic variants with impact on transcription of 
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LRP12 as a developmental and growth kinetics factor provides a new 
pathomechanism for highly differentiated epileptogenic brain tumors. 
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9. Abbreviations 
 
Abbreviation Full name 
% Percent 
°C Degrees Celsius 
$ Dollar 
6A/SB1 cells Carcinogen transformed MSU-1 cells 
AED Antiepileptic drug 
AHS Ammon’s horn sclerosis 
ANOVA Analysis of variance 
BME Basal Medium Eagle 
bp Base pair 
BRAF  Serine/threonine-protein kinase B-Raf 
BSA Bovine serum albumin 
C. elegans Caenorhabditis elegans 
CA Cornu Ammonis 
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CAG promoter Cytomegalovirus early enhancer 
element and chicken beta-actin 
promoter 
CBA promoter Chicken beta-actin promoter 
CBZ Carbamazepine 
CD34 Stem cell marker protein 
cDNA Complementary DNA 
cm Centimetre 
CMV promoter Cytomegalovirus promoter 
CNS Central nervous system 
CPS Complex partial seizures 
CUB C1r/C1s, Uegf, Bmp1 
CUX1 Cut-like homeobox 1 protein 
Cy3 N,N-(dipropyl)-
tetramethylindocarbocyanine 
DAPi 4’, 6-Diamidino-2-phenylindol 
DIV Day in vitro 
DMEM Dulbecco’s Modified Eagle Medium 
DNA Deoxyribonucleic acid 
Abbreviations 
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E Embryonic day 
EGF Epidermal Growth Factor Receptor  
egl External granular layer 
epl External pyramidal layer 
ERK Extracellular signal-regulated kinases 
et al. et alii 
F Female 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
GAPDH Glycerinaldehyd-3-phosphat-
Dehydrogenase 
GFAP Glial fibrillary acidic protein 
GG Ganglioglioma 
GM130 cis-Golgi matrix protein 
h Hour 
H&E Hematoxylin & eosin 
HA Human influenza hemagglutinin epitope 
HBSS Hank’s Balanced Salt Solution 
Abbreviations 
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HEK293T Human embryonic kidney cell line 239T 
hrGFP Humanized recombinant GFP 
HWE Hardy–Weinberg equilibrium 
IBE International Bureau for Epilepsy 
IDH1 Isocitrate dehydrogenase 1 (NADP+), 
soluble 
igl Internal granular layer 
IHC Immunohistochemistry 
ILAE International League Against Epilepsy 
IPCs Intermediate progenitor cells 
kDa Kilodalton 
kg Kilogram 
LDB2 LIM-domain-binding 2 protein 
LDLR Low-density lipoprotein receptor 
LDLRA LDL-receptor class A 
legl Lower external granular layer 
LEV Levetiracetam 
  
Abbreviations 
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LIM Protein domain named after the LIN-11, 
ISL-1 and MEC-3 proteins in 
Caenorhabditis elegans 
LRP3 Low-density lipoprotein receptor-related 
protein 3 
LRP9 Low-density lipoprotein receptor-related 
protein 9 
LRP12 Low-density lipoprotein receptor-related 
protein 12 
LTG Lamotrigine 
M Male 
mA Milliampere 
MEK Dual threonine and tyrosine recognition 
kinase that phosphorylates and 
activates mitogen-activated protein 
kinase 
mg Milligram 
MIBP Muscle Integrin Binding protein 
MIG-13 Evolutionally conserved protein MIG-13, 
required for anterior QR migration in C. 
elegans  
Abbreviations 
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min Minute 
ml Milliliter 
ml Molecular layer 
mM Millimolar 
mRNA Messenger RNA 
ms Millisecond 
MSU-1 cells Non-tumorigenic fibroblast cells 
MZ Marginal zone 
n Number 
n.k Not known 
NeuN Neuronal Nuclei protein 
NG108-15 Hybrid of murine neuroblastoma and rat 
glioma cells 
NFM Neurofilament protein 
ng Nanogram 
NGS Normal goat serum 
OPCs Oligodendrocytes precursor cells 
OXC Oxcarbazepine 
Abbreviations 
 122 
P Post natal 
p p-value 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PDGFRA Platelet-derived growth factor receptor, 
alpha polypeptide  
Pen Strep Penicillin-Streptomycin 
PFA Paraformaldehyde 
PSD95 Postsynaptic density protein 95 
PTEN Phosphatase and Tensin homolog gene 
PTZ Pentylenetetrazole 
qRT-PCR Real-time-quantitative PCR  
rAAV Recombinant adeno-associated virus 
RACK1 Receptor for Activated C Kinase 1 
RAF Rapidly accelerated fibrosarcoma 
protein 
RAS Rat sarcoma protein 
RFP Red fluorescent protein 
RGS Radial glial cells 
Abbreviations 
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RNA Ribonucleic acid 
Rs Reference SNP 
SARA SMAD Anchor for Receptor Activation 
SDS-Page Sodium dodecyl sulfate polyacrylamide 
gel electrophoresis 
sec Second 
SEM Standard error of the mean 
sGTCS Secondary generalized tonic clonic 
seizures 
shRNA Small hairpin RNA 
SNP Single nucleotide polymorphism 
SNPs Short neural precursors 
SPS Simple partial seizures 
SSCP Single-strand conformation 
polymorphism 
ST7 Suppressor of tumorigenicity 7 
STAT5a Signal transducer and activator of 
transcription 5A 
SVZ Subventricular zone 
Abbreviations 
 124 
t-test Student’s t-test 
TF Transcription factor 
TLE Temporal lobe epilepsy 
TP53 Tumor protein 53 gene 
TPM Topiramate 
TSC2 Tuberous sclerosis protein 2 
U-test Mann–Whitney test 
U6 promoter RNA polymerase III promoter 
U6-hrGFP pAM/U6-shRNA-CBA-hrGFP 
uegl Upper external granular layer 
VPA Valproate 
vs. Versus 
VZ Ventricular zone 
WHO World Health Organization 
WT Wild type 
μF Microfarad 
g Microgram 
m Micrometer 
Abbreviations 
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2-test Chi-squared test 
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